References

References

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

Abbott, B.J., Developmental Therapeutics Program,National Cancer Institute, National Institutes ofHealth, U.S. Department of Health and HumanServices, letter to C. Schleicher, M.D., President,Mankind Research Foundation, Silver Spring, MD,October 24, 1978.Abbott, B.J., Developmental Therapeutics program,National Cancer Institute, National Institutes ofHealth, U.S. Department of Health and HumanServices, Bethesda, MD, personal communications,1988 and 1989.Acevedo, H.F., Campbell-Acevedo, E., and Kloos,W.E., “ExPRxsionof Human chorion.ic ~ph-like Material in Coagulase Negative Staphylococ-cus Species,” Infect. Immun. 50(3):860-868, 1985.Acevedo, H.F., Pardo, M., Campbell-Acevedo, E.,et al., “Human Choriogonadotropin-like Materialin Bacteria of Different Species: Electron Micros-copy and Immunocytochemical Studies with Mono-clinal and Polyclonal Antibodies,” J. Gen. Micro-biol. 133:783-791, 1987.Acevedo, H.F., Slifkin, M.: Pouchet, G.R., et al.,“Immunohistochemical Localization of a Chori-onic Gonadotropin-like Protein in Bacteria IsolatedFrom Cancer Patients,” Cancer 41:1217-1229,1978.Achterberg, J., Imagery in Healing: Shamanism andModern Medicine (Boston, MA: New ScienceLibrary, 1985).khterberg, J., “Recommendations for a Disci-plinedInquiry: Unconventional CancerTreatments,’typescript, March 10, 1990.Achterberg, J., Block, K., Coh, J., Fink, J.,Hildebrand, G., Wrner, M., O’Regan, B., Weil, A.,“Joint letter from selected OTA Advisory PanelMembers,” March 25, 1990.Adams, D., Member, Friends of Dr. Revici, Washing-ton, DC, personal communication, April 1987.Adams, J., Clinical Research Pharmacist, Divisionof Cancer Treatment, National Cancer Institute,National Institutes of Health, U.S. Department ofHealth and Human Services, Bethesda, MD, per-sonal communication, August 1988.Ader,R. (ed.),Psychoneuroimmurwlogy (New YorlqNY: Academic Press, 1981).Ader, R., “Clinical Implications of Psychoneuroim-munology,” J. Dev. Behav. Pediatr. 6(6):357-358,1987.Ader, R., and Cohen, N., “Conditioned Immuno-pharmacologic Responses,” Psychoneuroimmunol-ogy, R. Ader (cd.) (New York, NY: AcademicPress, 1981).

14.

15.

16.

17.

18.

19.

20.

21.

22.

22a.

23.

24.

25.

26.

27.

28.

29.

30.

Ader, R., Greta, L.J., and Cohen, N., “ConditioningPhenomena and Immune Function,” Ann. N.XAcad. Sci. 496:532-544, 1987.Aihara, H., Acid and Alkaline (Oroville, CA:George Ohsawa Macrobiotic Foundation, 1986).Aihara, H., Basic Macrobiotics (New York, NY:Japan Publications, 1985).Alliance for Alternative Medicine, “The Alliancefor Alternative Medicine,” unpublished positionpaper, Liberty Lake, WA, November 20, 1987.Alliance for Alternative Medicine, “Dear Friend,”form letter, Liberty Lake, WA, undated.Alliance for Alternative Medicine, “WelcomesMembers of Congress and Invited Guests to OurScreening of the Acclaimed Film, ‘Hoxsey: QuacksWho Cure Cancer?’ “ undated pamphlet.Alternatives, “Halfis Formally Launched,” Alterna-tives 1(1):1,4, 1986.Alvarez, W. C., “Origin of the So-called Auto-Intoxication Symptoms,” JJLM.A. 72:8-13, 1919.American Biologics, Tijuana, Mexico, patient bro-chure, undated.American Cancer Society, Unproven Methods ofCancer Management, (untitled), CA 11(2):67-68,1961.American Cancer Society, “Unproven Methods ofCancer Treatment: Livingston Vaccine,” CA 18(1):46-47, 1968.American Cancer Society, “Unproven Methods ofCancer Management: Hydrazine Sulfate,” CA 26(2):108-110, 1976.American Cancer Society, ” 1986 Cancer Facts andFigures, “ New York, NY, 1986.American Cancer Society, Cancer Response Sys-tem, “Fresh Cell Therapy,” typescript, October 5,1987.American Cancer Society, Cancer Response Sys-tem, “Immuno-Augmentative Therapy-Dr. Law-rence Burton,” Number 8,329, typescript, October1987.American Cancer Society, “Unproven Methods ofCancerManagement,” pamphlet, 87-25M-No. 3028,1987.American Cancer Society, “Unproven Methods ofCancer Management: International Association ofCancer Victors and Friends,” CA 39(1):58-59,1989.American Cancer Society, “Unproven Methods ofCancer Management: Macrobiotic Diets for theTreatment of Cancer,” CA 39(4):248-251, 1989.

–257–

258 ● Unconventional Cancer Treatments

31.

32.

33.

34.

35,

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

American Cancer Society, “Unproven Methods ofCancer Management: Revici Method,” CA 39(2):119-122,1989.American Cancer Society, “Immuno-Augmenta-tive Therapy,” statement on “Unproven Methodsof Cancer Management,’ typescript, undated.American Cancer Society, Delaware Division, Inc.,‘‘UnprovenMethods Information Service,” mimeo-graph, Wilmington, DE, March 1987.American College of Physicians, ‘Parenteral Nutri-tion in Patients Receiving Cancer Chemotherapy,’Ann. Intern. Med. 110(9):734-736, 1989.American Health Foundation, “bw Fat Diet inStage II Breast Cancer— Randomized Study,”(protocol), E.L. Wynder, Principal Investigator,typescript, undated.American Home Products Corp. v. F. T.C., 695 F.2d681,687 (3d Cir. 1982).American Journal of Law and Medicine, “SelectedRecent Court Decisions: Third-Party Reirnbursement—Laetrile Treatment—Free v. Travelers InsuranceCo.,” Am. J. Law Med. 9(1):103-116, Spring 1983.American Medical Association, “Proceedings ofthe Annual Meeting of the House of Delegates,”1913-1975.American Medical Association, Council on Phar-macy and chemistry, “Cancer and the Need forFacts,” J.A.M.A. 139(2):93-98, 1949.American Medical Association, “Proceedings ofthe Annual Meeting of the House of Delegates, ”1961-1969.American Medical Association, “Proceedings ofthe Annual Meeting of the House of Delegates,”1967.American Medical Association, Digest of OfficialActions, 1969-1978.American Medical Association, Council on Foodsand Nutrition, “Zen Macrobiotic Diets,” J.A.M.A.218(3):397, 1971.American Medical Association, “Proceedings ofthe Annual Meeting of the House of Delegates,”1975.American Medical Association, Council on Scien-tific Affairs, “Dimethyl Sulfoxide: Controversyand Current Status-1981,” typescript.American Medical Association, “DA~A Evalua-tion Update: Hyperthermia Treatment for Cancer,’unpublished report reflecting the views of DA3TApanelists and reports in the scientific literature as ofSeptember 1984.American Medical Association, 1986 Annual Re-port (Chicago, IL: American Medical Association,1986).American Society of Clinical Oncology, Subcommitt-ee on Unorthodox Therapies, “Ineffective Cancer

49.

50.

51.

52.

53.

54.

55.

56.

56a.

57.

58.

59.

60.

Therapy: A Guide for the Layperson,” J. CZin.Oncol. 1(2):154-63, February 1983.Anderson, A., Jr., ‘‘The Politics of Cancer: How DoYou Get the Medical Establishment to Listen?”New York 7(30):42-46, 1974.Andrews, L. B., Deregulating Doctoring: Do Medi-cal Licensing Luws Meet Tockzy’s Health CareNeeds? (Emmaus, PA: People’s Medical Society,1983).Arizona v. Wickham, Sup. Ct., Co. of Maricopa, Az.CR 1384420 (1984), as cited in R.D. Schwartz, andR.L. Burke, “hgal Constraints on the Availabilityof Unorthodox Cancer Treatments: Consumer Pro-tection Viewpoint,” prepared for the Office ofTechnology Assessment, U.S. Congress, Washing-ton, DC, April 1988.Arnan, M., and DeVries, L.E., “Effect of Ozone/Oxygen Gas Mixture Directly Injected Into theMammary Carcinoma of the Female C3H/HEJMice,” J. Holistic Med. 7(1):31-37, 1985.Arnold, C., “The Macrobiotic Diet: A Question ofNutrition,” Oncol. Nurs. Forum 11(3):50-53, 1984.Arntson, P., “The Network: How Patients barnAbout and Gain Access to Unorthodox CancerTreatments,” prepared for the Office of TechnologyAssessment, U.S. Congress, Washington, DC, March1988.Arntson, P., Northwestern University, Evanston, IL,personal communication, 1987.Aronson, N., Manager, Technology Evaluation andCoverage, Blue Cross and Blue Shield Association,Chicago, IL, personal communications, August1988 and September 1988.Association of Food and Drug Officials of theUnited States, Quarterly Bulletin: Uniform StateFood, Drug and Cosmetic Bill, Revised Form, 2dSupplemental Issue, 1969.Athar, M., Raza, H., Bickers, D.R., et al., “Inhibi-tion of Benzoyl Peroxide-mediated ‘llunor Promo-tion in 7,12-Dirnethylbenz(a)anthracene-initiatedSkin of Sencar Mice by Antioxidants Nordihy-droguaiaretic Acid and Diallyl Sulfide,” J. Invest.Derrnatol. 94:162-165, 1990.Ausubel, K., “The Troubling Case of HarryHoxsey,” New Age, pp. 4347,49,78-79,86, July/August 1988.Ausubel, K., and Salveson, C., producers, “Hoxsey:Quacks Who Cure Cancer?” Realidadl?roductions,Inc., Santa Fe, NM, 1987.Avery, R. J., Office of Cancer Communications,National Cancer Institute, National Institutes ofHealth, U.S. Department of Health and HumanServices, letter to G. Dego, University of London,August 24, 1982.

References .259

61.

62.

63.

64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

74.

75,.

76,

77.

Awang, D.V.C., “Commercial Taheebo Lacks Ac-tive Ingredient,” Can. Pharm. J. 121(5):323-326,1988.BackUs, B.T, and Affronti, L.F., “Tuor Associ-ated Bacteria Capable of Producing a HumanChoriogonadotropin-like Substance,” I#ect. Immun.32:1211-1215, 1981.Bailar, J. C., “Rethinking the War on Cancer,”Issues in Science and Technology, pp. 16-21, Fall1987.Bailar, J. C., letter to H. Gelband, Office of Technol-ogy Assessment, U.S. Congress, October 21, 1988.Bailar, J, C., and Smith, E.M., “Progress AgainstCancer?” N. Engl. J. Med. 314(19):1226-1232,1986.Baker, M. S., Kessler, L.G., and Smucker, R. C.,“The Cost of Treating Cancers of Thirteen Differ-ent Sites Among Medicare Beneficiaries,’ NationalCancer Institute, National Institutes of Health, U.S.Department of Health and Human Services, draft,1988.Bannister, G., Ginsburg, R., and Shneerson, J.,“CardiacArrest Due to Liquorice-Induced Hypoka-lemia,” B.M.J. 2:738-739, 1977.Barrett, S., “A Special Report by the AmericanCouncil on Science and Health on United Sciencesof America, Inc. ” American Council on Scienceand Health, New York, ~, April 1987.Barrett, S., “Bogus Claims for H202 Stopped,”Nutrition Forum 5(8): 68, 1988.Barrett, S., Editor, Nutrition Forum, Allentown, PA,personal communication, February 1990.Batson, E., Senior Scientist, Department of Technol-ogy Assessment, American Medical Association,Chicago, IL, personal communication, December1987.Belkin, M., and Fitzgerald, D. B., “Thmor-Damaging Capacity of Plant Materials. 1. PlantsUsed as Cathartics,” J. Natl. Cancer Inst. 13:139-155, 1952.Benedict, D., Confessions of a Kamikaze Cowboy(North Hollywood, CA: Newcastle Publishing,1987).Benjamin, H., Wellness Community, Santa Monica,CA, personal communication, January 31, 1989.Berger, M., and Schmiihl, D., “Studies on the‘Ibmor-Inhibiting Efficacy of Iscador in Experimen-tal Animal Tumors,” J. Cancer Res. Clin. Oncol.105(3):262-265, 1983.Berkow, R., Editor-in-Chief, The Merck ManuuZ ofDiagnosis and Therapy, 15th edition, West Point,PA, letter, September 26, 1988.“Biography of Dr. Hans A. Nieper,” mimeographobtained from the A. Keith Brewer Science Library,Richland Center, WI, undated.

78.

79.

80.

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

92.

93.

94.

Bio-Medical Center, Information sheet on HoxseyTherapy, typescript, undated.BlackStein, M.E., and Bergsagel, D.E., ‘The Treat-ment of Cancer Patients With Antineoplastons andthe Burzynski Clinic in Houston, Texas,’ Report tothe Ministry of Health, Province of Ontario, type-script, 1982.Bland, J., and Bradford, R., cited in L. Chaitow,“Bland Attacks ‘Fad’ for Hydrogen Peroxide,”Townsend Letter for Doctors 58:204, May 1988.Block, J.B., Serpick, A.A., Miller, W., et al., “EarlyClinical Studies With Lapachol (NSC-11905),”Cancer Chemother. Reports Part 2 4(4):27-28,1974.Block, K.I., Adviso~ Panel Member, Evanston, IL,letters, July 1987 and March 1990.Block, K. I., “New Clinical Care Model: Applica-tions to Cancer Patient Care,” unpublished manu-script, 1988.Block, K.I., and Gyllenhaal, C., “Nutrition: AnEssential Tool in Cancer Therapy,’ typescript, May1990.Blodgett, N., “States Tackle Health Care Frauds,”Am. Bar Assoc. J. 73:32, October 2, 1987.Blue Cross and Blue Shield Association, “TECEvaluation: Ozone Therapy for Cancer,” unpub-lished mimeograph, Chicago, IL, November 1987.Blue Cross and Blue Shield Association, “Technol-ogy Evaluation Criteria, ” Chicago, IL, 1987.Blue Cross and Blue Shield Association, “TECProgram, ” unpublished mimeograph, Chicago, IL,undated.Bond, W., Research Microbiologist, Centers forDisease Control, U.S. Department of Health andHuman Services, consultant to Pan AmericanHealth Organization (PAHO), letter report to R. St.John, M.D., Chief, Epidemiology, PNO, July 5,1985.Bonfiglio, J., Director, Professional Education Pro-gram, American Cancer Society, Atlanta, GA,personal communications, July 1988, 1989, March26, 1990, and May 1990.Bonomi, P.D., Finkelstein, D.M., Ruckdeschel,J. C., et al., “Combination Chemotherapy VersusSingle Agents Followed by Combination Chemo-therapy in Stage IV Non-Small-Cell Lung Cancer:A Study of the Eastern Cooperative OncologyGroup,” J. Clin. Oncol. 7(11):1602-1613, 1989.Borysenko, J., and Rothstein, L., Minding the Body,Mending the Mind (Reading, MA: Addison-Wesley, 1987).Borysenko, M., “Area Review: Psychoneuroimmu-nology. The Immune System: An Overview,” Ann.Behav. Med. 9(2):3-10, 1987.Bott, V., Anthroposophical Medicine: SpiritualScience and the Art of Healing (New York NY:

260 ● Unconventional Cancer Treatments

94a.

95.

96.

97.

98.

99.

100.

101.

102.

103.

104.

105.

Thorson’s Publishers, Inc., Rudolf Steiner Press,1984).Bouviav. Superior Court (Glenchur) 179 Cal.App.3d1127, 225 Cal.Rptr. 297 (Ct.App. 1986), revieweddenied (Cal. June 5, 1986).Bowman, B., Kushner, R.F., Dawson, S. C., et al.,“Macrobiotic Diets for Cancer Treatment andPrevention,” J. Clin. Oncol. 2(6):702-710, 1984.Bradford, R.W., Allen, H.W., and Culbert, M.L.,Oxialdogy: The Study of Reactive Oxygen ToxicSpecies (ROTS) andtheirA4etabolism in Health andDisease (Chula Vista, CA: The Bradford Founda-tion).Bradford, R., Culbert, M.L., and Allen, H.W.,International Protocols for Individualized, Inte-grated Metabolic Programs in Cancer Manage-ment (Los Altos, CA: The Robert W. BradfordFoundation, 1981).Bradford, R.W., and Culbert, M.L., “HydrogenPeroxide, ’ Health Consciousness 10(1):28-29,1989.Bradner, W.T, and Claridge, C.A., “ScreeningSystems,” Antineoplastic Agents, W.A. Remers(cd.) (New York, NY: John Wiley & Sons, 1984).Braico, K.T., Humbert, J.R., Terplan, K.L., et al.,“Laetrile Intoxication. Report of a Fatal Case,” N.Engl. J. Med. 300(5):238-240, 1979.Breo, D.L., Extraordinary Care (Chicago, IL:Chicago Review Press, 1986).Bridge, L.R., Benson, P., Pietroni, P. C., et al.,“Relaxation and Imagery in the Treatment of BreastCancer,” B.M.J. 297:1169-1172, 1988.Briggs, B. E., Transcript of disciplinary actionagainst him by Minnesota board, April 19, 1983.Brown, H., “Cancer Quackery: What Can You DoAbout It?” Nursing75 5(5):24-26, May 1975.Brown, H.G., ‘‘Worthless Methods of Cancer Man-agement,” Cancer Manual 7th ed. (Boston, MA:American Cancer Society, 1986).

105a. Brown, P.A., M.D., chairman of the Board,

106.

107.

108.

109.

110.

111.

MetPath, letter to J.J. Zavertnik, M.D., October 30,1981.

Brown, R.K., AIDS, Cancer, and the MedicalEstablishment (New York, NY: Speller, 1986).Brown, V., and St.ayman, S., Macrobiotic Miracle:How a Vermont Family Overcame Cancer (NewYork, NY: Japan Publications, 1984).Brucher, H.W., Letter to the Editor, J.A.M.A.261(7):987, 1989.Biihler, W., and Leroi, R., “Cancer as a Disease ofOur Times,” Soziale Hygiene 19:1-11, 1969.Burk, D., and Nieper, H.A., “Problems of EarlyCancer Diagnosis and Therapy,” AgressoZogie11(1):1-7, 1970.Burlington, B., Food and Drug Administration, U.S.Department of Health and Human Services, Rock-

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

vine, MD, personal communication, April 1988.Burnet, F.M., “The Concept of ImmunologicalSurveillance,” Prog. Exp. Tumor Res. 13:1-27,1970.Burton, L., “Carcinogenic Effects of an ExtractableLarval lbmor Agent,” Trans. N.r Acad. Sci.17(3):301-308, 1955.Burton, L., Statement at A Hearing on the Immuno-Augmentative Therapy of Dr. Lawrence Burton,hearing before Congressman Guy V. Molinari, NewYork, NY, January 15,1986.Burton, L., Director, MI’ Ltd., personal communi-cation, Freeport, Grand Bahama Island, September1987.Burton, L., Director, L4T Ltd., letters to R. Herd-man, Assistant Director, Office of TechnologyAssessment, U.S. Congress, March 3, 1988 andNovember 17, 1989.Burton, L., and Friedman, F., “Detection of ‘Ibmor-inducing Factors in Drosophila,” Science 124:220-221, 1956.Burton, L., Friedman, F., and Kassel, R., ‘Isolationof Two Oncolytic Fractions From Mouse LeukemicTissue,” Proceedings of the American Associationfor Cancer Research 3:308, 1962.Burton, L., Friedman, F., and Kassel, R., “Methodsfor Determination and Alteration of Titers of aComplex of Factors Present in Blood of NeoplasticMice,” Trans. N.Y Acad. Sci. Ser. II, 25:33-38,1962.Burton, L., Friedman, F., Kassel, R., et al., “ThePurification and Action of Nor Factor ExtractedFrom Mouse and Human Neoplastic Tissue,”Trans. N.Y Acad. Sci. 21(8):700-707, 1959.Burton, L., Friedman, F., and Mitchell, H.K., “ThePurification of an Inherited ‘Ihmor-inducing Factorin Drosophila melanogaster,” Cancer Research16:880-884, 1956.Burton, L., Friedman, F., and Mitchell, H.K., “AThmor-inducing Factor in Drosophila meZanogas-ter: II. Its Clmacteristics and Biological Nature,”Ann. N.X Acad. Sci. 68(2):356-365, 1957.Burton, L., Harnly, M.H., and Kopac, M.J., “TheActivity of a ‘Ihmor Factor in Drosophila Develop-ment,” Cancer Res. 16:402-407, 1956.Burzynski Research Institute, Inc., Houston, TX,brochure, December 1986Burzynski Research Institute, Inc., Houston, TX,‘‘FDA Grants Permission for Independent ClinicalStudy of Experimental U.S. Biotechnological Can-cer Treatment,” press release, mimeograph, March24, 1989.Burzynski Research Institute, Inc., Houston, ‘IX,“Dramatic Improvement of Prostate Cancer Pa-tients on Experimental U.S. Biotechnological Can-cer Treatment,” press release, undated.

References ● 261

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

Burzynski Research Institute, Inc., Houston, TX,“ExperimentalU.S. Biotechnological CancerTreat-ment to be Tested by Major European Pharmaceutic-al Company,” press release, undated.Burzynski, S.R., “Biologically Active Peptides inHuman Urine: I. Isolation of a Group of Medium-sized Peptides, “ Physiol. Chem. Phys. 5:437, 1973.Burzynski, S.R., “A Testing Procedure to AidDiagnosis of Cancer and Evaluate Progress ofCancer Therapy,” U.S. patent #4,444,890, issuedApril 24, 1984.Burzynski, S. R., “Purified Antineoplaston Frac-tions and Methods of Treating Neoplastic Disease,’U.S. patent #4,470,970, issued September 11,1984.Burzynski, S.R., “Purified Antineoplaston Frac-tions and Methods of Treating Neoplastic Disease,’U.S. patent #4,558,057, issued December 10,1985.Burzynski, S.R., “Purified Antineoplaston Frac-tions and Methods of Treating Neoplastic Disease,’U.S. patent #4,559,325, issued December 17,1985.Burzynski, S.R., “Antineoplastons: History of theResearch (I),” Drugs Exp. CZin. Res. Suppl. 1, XII,pp. 1-9, 1986.Burzynski, S.R., “Toxicology Studies on Antineo-plaston AS2-5 Injections in Cancer Patients,”Drugs Exp. CZin. Res. Suppl. 1, XII, pp. 17-24,1986.Burzynski, S.R., “Response to Site Visit toBurzynski Research Institute on 15 November 1982and Report by Drs. M.E. Blackstein, and D.E.Bergsagel,” typescript, undated.Burzynski, S.R., Bumynski, B., and Mohabbat,M.O., “Toxicology Studies on AntineoplastonAS2-1 Injections in Cancer Patients” Drugs Exp.CZin. Res. Suppl. 1, XII, pp. 25-35, 1986.Burzynski, S.R., and Kubove, E., “Initial ClinicalStudy With Antineoplaston A2 Injections in CancerPatients With Five Years’ Follow-up,’ Drugs Exp.CZin, Res. Suppl. 1, XIII, pp. 1-12, 1986.Burzynski, S.R., and Kubove, E., “ToxicologyStudies on Antineoplaston A-10 Injections in Can-cer Patients,” Drugs Exp. CZin. Res. Suppl. 1, XII,pp. 47-55, 1986.Burzynski, S.R., and Kubove, E., “Initial ClinicalStudy With Antineoplaston A2 Injections in CancerPatients With Five Years’ Follow-up,” Drugs Exp.CZin. Res. Suppl. 1, XIII, pp. 1-12, 1987.Burzynski, S.R., and Kubove, E., “Phase I ClinicalStudies of Antineoplaston A3 Injections,” DrugsExp. CZin. Res. Suppl. 1, XIII, pp. 17-29, 1987.Burzynski, S.R., Kubove, E., and Burzynski, B.,“Phase I Clinical Studies of Antineoplaston A5Injections,” Drugs Exp. CZin. Res. Suppl. 1, XIII,pp. 3743, 1987.Burzynski, S.R., I_.oo, T.L., Ho, D.H., et al.,‘‘Biologically Active Peptides in Human Urine. III.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

Inhibitors of the Growth of Human Leukemia,Osteosarcoma, and HeLa Cells,” PhysioZ. Chem.Phys. 8(3):13-22, 1976.Burzynski, S.R., Stolzmann, Z., Szopa, B., et al.,“Antineoplaston A in Cancer Therapy (I),” Phys-iol. Chem. Phys. 9:485, 1977.Buyse, M., Zeleniuch, J.A. and Chalmers, T. C.,‘‘Adjuvant Therapy of Colorectal Cancer: Why WeStill Don’t Know,” J.A.M.A. 259(24):3571-3578,1988.Byar, D. P., “Why Data Bases Should Not ReplaceRandomized Clinical Trials,” Biometrics 36:337-342, 1980.Byar, D., Simon, R.M., Friedewald, W.T., et al.,‘ ‘Randomized Clinical Trials: Perspectives on SomeRecent Ideas,” N. Engl, J. Med. 295:74-80, 1976.Cairns, J., “The Treatment of Diseases and the WarAgainst Cancer,’ Sci. Am. 253(5):51-59, 1985.Caisse, R.M., letter to W.G. Brown, Deputy Minis-ter, Department of Health, October6, 1958. Copy incollection at Archives of Ontario, Ministry ofCulture and Communications, Toronto, Ontario.Cal. Health & Safety Code, ~ 1700-1722, West1979 & Supp., 1987.Canopy, A., Pega.lis & Wachsman, P. C., GreatNeck, NY, personal communication, May 17,1990.Cameron, E., Hyaluronidase and Cancer (NewYork NY: Pergamon Press, 1966).Cameron, E., Linus Pauling Institute of Science andMedicine, personal communication, July 1988.Cameron, E., Linus Pauling Institute of Science andMedicine, letter, February 27, 1990.Cameron, E., and Campbell, A., “The Orthomol-ecular Treatment of Cancer. II. Clinical Trial ofHighdose Ascorbic Acid Supplements in Ad-vanced Human Cancer,’ Chem. BioZ. Interact.9:285-315, 1974.Cameron, E., and Pauling, L., ‘The OrthomolecularTreatment of Cancer. I. The Role of Ascorbic Acidin Host Resistance,” Chem. Biol. Interact. 9:273-283, 1974.Cameron, E., and Pauling, L., “SupplementAscorbate in the Supportive Treatment of Cancer:Prolongation of Survival Times in Terminal HumanCancer,” Proc. Nat. Acad. Sci. U.S/l. 73:3685-3689,1976.Cameron, E., and Pauling, L., “SupplementalAscorbate in the Supportive Treatment of Cancer:Reevaluation of Prolongation of Survival Times inTerminal Human Cancer,” Proc. Nat. Acad. Sci.U.S.A. 75:4538-4542, 1978.Cameron, E., and Pauling, L., Cancer and VitaminC (Menlo Park, CA: Linus Pauling Institute ofScience and Medicine, 1979).

262 ● Unconventional Cancer Treatments

159.

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

Cameron, E., Pauling, L.,andhibovitz, B., “Ascor-bic Acid and Cancer: A Review,” Cancer Res.39:663-681, 1979.Cameron, E., and Rotman, D., “Ascorbic Acid, CellProliferation, and Cancer,” Luncet i:542, 1972.Campbell, G.D., Steinberg, M.H., and Bower, J.D.,“Ascorbic-acidI nduced Hemolysis in G6-PD Defi-ciency,” Ann. Intern. Med. 82:810, 1975.Cancer Control Society, programs for 15th (1987),16th (1988), and 17th (1989) Annual Conventions,Los Angeles, CA.Cancer Control Society, “Non-Toxic Therapies andDiagnostic Tests Directory,” unpublished mimeo-graph, Los Angeles, CA, March 1988.Cancer Control Society, “Patients Treated WithNon-Toxic Cancer Therapies and Nutrition,” un-published mimeograph, Los Angeles, CA, March1988.Cancer Control Society, “Fact Sheet Taken Fromthe Articles of Incorporation,’ unpublished mimeo-graph, Los Angeles, CA, undated.Cancer Control Society, form letter to individualsrequesting information, Los Angeles, CA, undated.“Cancer Diet and Other Precautions,” typescript,obtained from the A. Keith Brewer Library, Rich-land Center, WI, 1984.Cannon, H., Associate Commissioner for Legisla-tive Affairs, Food and Drug Administration, U.S.Department of Health and Human Services, Rock-ville, MD, personal communication, April 16,1990.Carey, M.P., and Burish, TG., “Etiology andTreatment of the Psychological Side Effects Associ-ated With Cancer Chemotherapy: A Critical Reviewand Discussion, ” Psychol. Bull. 104(3):307-325,1988.Carswell, E., Old, L., Kassel, R., et al., “AnEndotoxin-induced Serum Factor That Causes Ne-crosis of hors,” Proc. Natl. Acad. Sci. U.S.A.72:3666-3670, 1975.Carter, J.P., Saxe, G.P., Newbold, V., et al.,“Cancers with Suspected Nutritional Links: Die-tary Management,” typescript, Nutrition Section,Tulane University School of Public Health andTropical Medicine, New Orleans, LA, February1990.Carter, S.K., “Clinical Aspects in the Design andConduct of Phase II Trials,” Cancer ClinicalTrials: Methods and Practice, M.E. Buyse, M.J.Staquet, and R.J. Sylvester (eds.) (Oxford, England:Oxford University Press, 1984).Carter, S.K., Newman, J.W., Rail, D., et al.,“Lapachol. NSC 11905. Clinical Brochure,” type-script, National Cancer Institute, National Institutesof Health, U.S. Department of Health and HumanServices, November 1967.

174.

175.

176.

177.

178.

179.

180.

181.

182.

183.

184.

185.

186.

187.

Case, C., Office of Cancer Communications, Na-tional Cancer Institute, National Institutes ofHealth, U.S. Department of Health and HumanServices, Bethesda, MD, personal communications,August 1987 and November 4,1988.Cassileth, B.R., Advisory Panel member, Univer-sity of Pennsylvania, Philadelphia, PA, personalcommunications, 1987.Cassileth, B.R., Lusk, E.J., Miller, D. S., et al.,‘‘Psychosocial Correlates of Survival in AdvancedMalignant Disease,“N.Engl.J.Med. 312(24):1551-1555, 1985.Cassileth, B.R., Lusk, E.J., Strouse, T.B., et al.,“Contemporary Unorthodox Treatments in CancerMedicine: A Study of Patients, Treatments, andPractitioners,’ Ann. Intern. Med. 101(1):105-112,July 1984.Cassileth, B.R., Troc~ B.J., Lusk, E.J., et al.,“Report of a Survey of Patients Receiving hnrnu-noaugmentative Therapy, ” University of Pennsyl-vania Cancer Center, unpublished, September 1987.Cereda, J.M., Trono, D., and Schi.fferli, J., ‘Liquor-ice Intoxication Caused by Alcohol-Free Pastis,”Lancet i:1442, 1983.Cerutti, P.A., “Prooxidant States and tumor Pro-motion,” Science 227(4685):375-381, 1985.Chao, P., Food and Drug Administration, U.S.Department of Health and Human Services, Rock-ville, MD, personal communication, February 23,1990.Chihara, G., “Antitumor and Immunological Prop-erties of Polysaccharides from Fungal Origin,”Mushroom Science (Proceedings of the loth Inter-national Congress on the Science and Cultivation ofEdible Fungi, France) 10 (Part 2):797-814, 1978.Chitnis, M.P., Adwankar, M.K., and Amonkar, A.J.,“Studies on High-dose Chemotherapy of Amygdalinin Murine P388 Lymphocytic Leukemia and P815Mast Cell Ixmkemia,” J. Cancer Res. Clin. Oncol.109:208-209, 1985.Chlebowski, R.T., Akrnan, S.A., and Block, J.B.,“Vitamin K in the Treatment of Cancer,” CancerTreat. Rev. 12:49-63, 1985.Chlebowski, R.T., Bulcavage, L., Grosvenor, M., etal., “Hydrazine Sulfate in Cancer Patients withWeight Loss. A Placebo-controlled Clinical Experi-ence,” Cancer 59(3):406-410, 1987.Chlebowski, R.T, Bulcavage, L., Grosvenor, M., etal., “Hydrazine Sulfate Influence on NutritionalStatus and Survival in Non-small-cell Lung Can-cer” J. Clin. Oncol. 8(1):9-15, 1990.Chlebowski, R. T., Heber, D., Richardson, B., et al.,“Influence of Hydrazine Sulfate on AbnormalCarbohydrate Metabolism in Cancer Patients withWeight Loss,” Cancer Res. 44:857-861, 1984.

References ● 263

188.

189.

190.

191.

192.

193.

194.

195.

196.

197.

198.

199.

200.

201.

202.

203.

Chowka, P.B., “Does N@dred Nelson Have anHerbal Cure for Cancer?” Whole Life Times pp.16-18, January-February 1984.Chowka, P.B., “Cancer 1988: Is a Healing Peace inthe Government’s War on Cancer Finally at Hand?”adapted from an article that appeared in East WestDecember 1987. Distributed by Project CURE,Washington DC, copyright P.B. Chowka, 1988.Chowka, P. B., Imperial Beach, CA, personal com-munication, 1988.Chrysler Corp. v. F.T.C., 561 F.2d 357,363 & n.5(D.C. Cir. 1977).Cinquina, A., “Cancer Victor Awarded Medical‘Rights’ in Court,” Cancer Victors Journal 22(1):1-2, Spring 1988.Cinquina, A., Executive Director and Editor, Inter-national Association of Cancer Victors and Friends,Inc., Playa del Rey, CA, personal communications,April 1988 and May 1988.City of Carter Lake v. Aetna, 604 F.2d 1052, 1056(8th Cir. 1979), as cited in G.P. Monaco, “Is theBenefit Package Fair to the Cancer Patient?’ paperpresented at the American Cancer Society; Work-shop on Employment, Insurance and the CancerPatient, New Orleans, LA, December 15-17, 1986.Clark v. Department of Professional Regulation,Board of Medical Examiners, 463 So. 2d. 328 rev.denied, 457 So.2d 693, as cited in R.D. Schwartz,and R.L. Burke, “Legal Constraints on the Availa-bility of Unorthodox Cancer Treatments: ConsumerProtection Viewpoint,” prepared for the Office ofTechnology Assessment, U.S. Congress, Washing-ton, DC, April 1988.Classen, J.N., Martin, R.E., and Sabagal, J., “Iatro-genic ksions of the Colon and Rectum,” South.Med. J. 68:1417-1428, 1975.Clayton, G.D., and Clayton, F.E. (eds.), Patty’sIndustrial Hygiene and Toxicology, 3rd rev. ed.(New York NY: John Wiley & Sons, 1981).Clement, B.R., Director, Hippocrates Health Insti-tute, “Dear Friend” letter, undated.Clement, J., Immunology Researching Centre, Ltd.,Freeport,Bahamas, personal communications, March26, 1987 (audiotape), June 1987, and September1987.Clement, J., “Immuno-Augmentative Therapy: ALogical and Natural Approach Towards the Controlof Cancer,” typescript, undated.Clement, R.J., Burton, L., and Lampe, G.N., “Peri-toneal Mesothelioma,” typescript, 1987, later pub-lished in Quantum Medicine 1(1 & 2):68-73, 1988.Clement, R.J., Burton, L., and Lampe, G.N., “Peri-toneal Mesothelioma,” Quantum Medicine 1(1 &2):68-73, 1988.Cliffdale Associates, Inc., 103 F.T.C. 110, 164-65,(1984).

204.

205.

206.

207.

208.

209.

210.

211.

212.

213.

214.

215.

216.

217.

218.

219.

220.

Clouse,L.H.,Mtertot heEditor, JAM-A. 261(7):987-988,1989.Coalition for Alternatives in Nutrition andHealthcare, Inc., “The Healthcare Rights Amend-ment,” HeaZthcare Rights Advocate 3(1):1, March1988.The Coalition for the Evaluation of AlternativeTherapy, “The Coalition,” form letter, Otho, IA,undated.Cochran, K.W., “Medical Effects,” The Biologyand Cultivation of Edible Mushrooms, S.T. Chang,and W.A. Hayes (eds.) (New York, NY: AcademicPress, 1978).Coeugniet, E.G., and Ele~ E., “Irnmunomodula-tion With Viscum album and Echinacea purpureaExtracts,” Onkdogie 10(3 Suppl.):27-33, 1987.Cohen, H. and Strampp, A., “Bacterial Synthesis ofa Substance Similar to Human Chononic Gona-dotropin,” Proc. Soc. Exp. BioZ. Med. 152:408410,1976.Cohen, M. A., Institute of Applied Biology, NewYork, NY, letter, August 24, 1987.Cohen, M.A., Statement, “Congressional PublicHearing Before Congressman Guy V. Molinari onAlternative or Non-traditional Cimcer Therapiesand Treatments by Emanuel Revici, MD,” NewYork, NY, March 18, 1988.Cohen, M.A., “On Emanuel Revici, MD,” type-script, September 12, 1988.Cohen, M.A., Coordinator, Revici Action Groups,New York, NY, memo, March 1990.Cole v. New York State Department of Education,463 N.Y.S. 2d 637 (N. Y.A.D. 3rd Department,1983), as cited in D.R. Gregory, “UnprofessionalConduct Justif@g License Revocation,” LegalAspects of Medical Practice 13(6):2, June 1985.Coley, W. B., “The Treatment of Malignant Tumorsby Repeated Inoculations of ErysipeZas: With aReport of Ten Original Cases,” Am. J. Med. Sci.105:487-511, 1893.Collin, J., “Unfair Discrimination Against HealthCare Practitioners,” Townsend Letter for Doctors61/62:393, August/September 1988.Collin, J., “The H202 crusades,” Townsend Letterfor Doctors 71:322, June 1989.Collin, J., Advisory Panel member, Port Townsend,WA, personal communications, March 1990, andApril 23, 1990 (letter).Collin, J., Advisory Panel member, Port Townsend,WA, informal survey comparing disciplinary ac-tions in 1989 to 1985 and earlier, personal commu-nication, March 1990.Colonial Life and Accident Insurance Company,‘‘Policy for Cancer and Other Specified Diseases”(Form HBDS), Columbia, SC, undated.

264 ● Unconventional Cancer Treatments

221.

222.

223,

224,

225.

226,

227,

228,

229,

230.

231.

232.

233.

234.

235.

236.

Commercial Clearing House, Inc., Medicare andMedicaid Guide (Chicago, IL: Commercial Clear-ing House, 1987).Commission for Alternative Systems of Medicine,“Alternative Medicine in the Netherlands,” Eng-lish summary, typescript, The Hague, 1981.Committee on the Health Education of the Public,California Medical Association, and Sampson, W.,et al., The Professional’s Guide to Health &Nutrition Fraud (San Francisco, CA: CaliforniaMedical Association, 1987).Cone, M., International Federation of Pharmaceuti-cal Manufacturers Associations, Geneva, Switzer-land, personal communication, July 1989.Consumers United Insurance Company, “NOW-med,” Washington, DC, November 1987.Consumers United Insurance Company, “Health-builder: Employee Group Health and Life Bene-fits,” Washington, DC, revised April 1988.Coop America, “Comprehensive Health and TermLife Insurance Plan,” Washington, DC, August1987.Cooper, D., Administrator, Security Unit, ClaimsDivision, Travelers Insurance Company, Hartford,CT, personal communication, June 1988.Cope, F.W., “A Medical Application of the LingAssociation-Induction Hypothesis: The High Potas-sium, Imw Sodium Diet of the Gerson CancerTherapy,” PhysioZ. Chem. Phys. 10(5):465-468,1978.Cousins, N., “Intangibles in Medicine: An Attemptat a Balancing Perspective,’ JJLM.A. 260(1 1):1610-1612,1988.Cragg, G.M., Natural Products Branch, Develop-mental Therapeutics Program, Division of CancerTreatment, National Cancer Institute, National In-stitutes of Health, U.S. Department of Health andHuman Services, letter to M. Mottl, July 23, 1986.Cragg, G.M., Natural Products Branch, Develop-mental Therapeutics Program, Division of CancerTreatment, National Cancer Institute, National In-stitutes of Health, U.S. Department of Health andHuman Services, Bethesda, MD, personal commu-nication, November 1, 1988.Craig, T.J., and Abeloff, M.D., “Psychiatric Symp-tomology Among Hospitalized Cancer Patients,”Am. J. Psychiatry 131:1323-27, 1974.Creagan, E.T., “Alternative Cancer Strategies,”typescript, July 10, 1987.Creagan, E.T., Mayo Clinic, Rochester, MN, per-sonal communication, July 1988.Creagan, E.T, Moertel, C.G., O’Fallen, J.R., et al.,“Failure of Highdose Vitamin C (Ascorbic Acid)Therapy to Benefit Patients With Advanced Can-cer,” N. Engl. J. Med. 301(13):687-690, 1979.

237,

238,

239,

240.

241.

242.

243.

244,

245,

246.

247.248.

249.

250.

251.

252.

253.

Culbert, M.L., correspondence, N. EngZ. J. Med.307(2):119, 1982.Culbert, M.L., ‘Live-Cell Therapy Comes of Age,”The Choice 14(1):1, 10-11, 1988.Culbert, M.L., Bradford, R.W., and Rodriquez, R.,“The Cancer Treatment Experience at AmericanBiologics-Mexico S.A. Medical Center: An Over-view of Patients and Treatments, ’ Townsend Letterfor Doctors 65:591-594, December 1988.Culliton, B.J., “Sloan-Kettering: The Trials of anApricot Pit— 1973,” Science 182:1000-1003, 1973.Cunniff, C., Medical Director, Blue Cross and BlueShield of New Jersey, Newark, NJ, personal com-munication, September 1988.Curran, W.J., “bgal Immunity for Medical Peer-Review Programs: New Policies Explored,” N.Engl. J. Med. 320(4):233-235, 1989.Curt, G., Division of Cancer Treatment, NationalCancer Institute, National Institutes of Health, U.S.Department of Health and Human Services, letter toC. Hennelly, March 17, 1986.Curt, G., Division of Cancer Treatment, NationalCancer Institute, National Institutes of Health, U.S.Department of Health and Human Services, Be-thesda, MD, personal communication, September1987.Curt, G., Division of Cancer Treatment, NationalCancer Institute, National Institutes of Health, U.S.Department of Health and Human Services, letter toJ. Ascensao, March 16, 1988.Curt, G.A., Katterhagen, G., and Mahaney, F.X.,“Immuno-Augmentative Therapy: A Primer on thePerilsofUnprovedTreatments,’ ‘J.A.M.A.255(4) :505-507, 1986.Dallis v. Aetna, 768 F.2d 1303 (llth Cir. 1985).Davignon, J. P., “Contaminated Laetrile: A HealthHazard,” N. Engl. J. Med. 297(24):1355-56, 1977.Davignon, J.P., Trissel, L.A., and Kleinman, L.M.,“Pharmaceutical Assessment of Amygdalin (Lae-tnle) Products,” Cancer Treat. Rep. 62:99-104,1978.Day, C., Assistant Claims Consultant, PrudentialInsurance Company of America, Parsippany, NJ,personal communication, September 1988.Defender Magazine, The Hoxsey Treatment: ARecord of Cancer Cures. Explaining the HoxseySystem of Treatment in Theory and Practice (Wic-hita, KS: Defender Publications, 1954).DeVita, V.T, Jr., “Principles of Chemotherapy,”Cancer: Principles and Practice of Oncology 3rdcd., V.T. DeVita, S. Hellman, and S.A.Rosenberg(eds.) (Philadelphia, PA: J.B. Lippincott, 1989).DeWys, W., Begg, C., Lavin, P., et al., “PrognosticEffect of Weight hss Prior to Chemotherapy inCancer Patients, “ Am. J. Med. 69:491-497, 1980.

References ● 265

254.

255.

256.

257.

258.

259.

260.

261.

262.

263.

264.

265.

266.

267.

268.

269.

270.271.

Dhawan, B.N., Patna.ik, G.K., Rastogi, R.P., et al.,“Screening of Indian Plants for Biological Activity.V.I.,” Indian J. Exp. Biol. 15:208, 1977.Diner, I. C., “lbmor Incidence in ICR/Albino andC57/B16JNIcrMale Mice Injected With OrganismsCultured From Mouse Malignant Tissues,” Growth38:507-517, 1974.Diner, I.C., and Donnelly, A.J., “Experiments WithMammalian Timor Isolates,” Ann. N.X Acad. Sci.174(2):655-674, 1970.Dombradi, C.A., and Foldeak, S., “ScreeningReport on the Antitumor Activity of PurifiedArctium Lappa Extmcts,” Tumori 52:173, 1966.Dorninigue, G.J., “Filterable, Cell-associated CellWall-deficient Bacteria in Renal Diseases,” CellWall-deficient Bacteria, Basic Principles and Clini-cal Significance, G.J. Dominigue (cd.) (l&ding,MA: Addison-Wesley, 1982).Donaldson, A.N., “Relation of Constipation toIntestinal Intoxication, ” J.A.M.A. 78:884-888,1922.Donnelly, W.J., Spykerboer, J.E., and Thong, Y.H.,“Are Patients Who Use Alternative MedicineDissatisfied With Orthodox Medicine?” Med. J.Aust. 142(10):539-541, 1985.Donsbach, K., Dr. Donsbach Tells You What YouAlways Wanted To Know About Glandular Extracts(Huntington Beach, CA: International Institute ofNatural Health Sciences, Inc., 1981).Donsbach, K., Hydrogen Peroxide, booklet, (nopublisher listed), 1987.Donsbach, K., and Walker, M., Dr. Donsbach TellsYou What You Always Wanted To Know AboutDMSO (Huntington Beach, CA: International Insti-tute of Natural Health Sciences, Inc, 1981).Dowling, St. J., ‘‘Lourdes Cures and Their MedicalAssessment,” J. R. Soc. Med. 77:634-638, 1984.Dreher, R., and Dreher, M., Nelson, MN, personalcommunication, October 1, 1988.Duke, J.A. ed.,HandbookofMedicinal Herbs (BocaRaton, FL: CRC Press, 1985).Dwyer, J.T., Dietz, W.H., Hass, G., et al., “Risk ofNutritional Rickets Among Vegetarian Children,”Am. J. Dis. Child. 133:134-140, 1979.Early Breast Cancer Trialists’ Collaborative Group,“Effects of Adjuvant Tamoxifen and of CytotoxicTherapy on MortaMy in Early Breast Cancer,” N.Engl. J. Med. 319(26):1681-92, 1988.Eckfelt, R.H., Executive Director, National HealthCare Anti-Fraud Association, Washington, DC,September 1988.Eden Ranch, “Price List,” Topanga, CA, undated.Edmonson, J., Advisory Panel member, MayoClinic, Rochester, MN, personal communication,Aprd 23, 1990.

272.

273.

274.

275.

276.

277.

278.

279.

280.

281.

282.

283.

284.

Eidinger, R.N., and Schapira, D.V., “Cancer Pa-tients’ Insight Into Their Treatment, Prognosis, andUnconventional Therapies,” Cancer 53(12):2736-2740, 1984.Eisele, J.E., and Reay, D.T., “Deaths Related toCoffee Enemas, ” J.A.M.A. 244(14):1608-1609, 1980.Ellison, N.M., Byar, D.P., and Newell, G.R.,“Special Report on Laetrile: The NCI LaetrileReview,” N. Engl. J. Med. 299(10):549-552, 1978.Eriguchi, N., Hara, H., Yoshi@ H., et al., “Che-mopreventive Effect of Antineoplaston AlO onUrethane-induced pulmonary Neoplasm in Mice,”J. Japan Soc. Cancer Ther. 23(7):1560-1565, 1988.Esko, E. (cd.), Doctors Look at Macrobiotics (NewYork NY: Japan Publications, 1988).Evans, M., E~ending the Art of Healing. AnIntroduction to Anthroposophical Medicine, pam-phlet, reprinted from “Work Arising From the Lifeof Rudolf Steiner,” Rudolf Steiner Press, undated.Evans, M.R., and Preece, A.W., “Viscum album—aPossible Treatment for Cancer?” BristolMed. Chir.J. 88i(325):17-20, 1973.Evers, M.S., “hgal Constraints on the Availabilityof Unorthodox Cancer Treatments: Freedom ofChoice Viewpoint,” prepared for the Office ofTechnology Assessment, U.S. Congress, June 1988.Evers, M. S., Attorney, Dothan, AL, letters, June 21,1988, and September 6, 1989.Federal Managers Association, “Federal ManagersHealth Benefit Plan,” Washington, DC, January1988.Federal Trade Commission, History Sheet, GeneralNutrition, kc., Docket No. 9175, September 9,1989.Federal Trade Commission v. Pharmtech Research,Znc., 576 F. Supp. 294 (D.D.C. 1983).Fedemtion of State Medical Boards, Inc., adaptedfrom Guiak to the Essentials of a Modern MedicalPractice Act, 1985 Revision (Fort Worth, TX:1985), as cited in M. Evers, “Legal Constraints onthe Availability of Unorthodox Cancer Treatments:Freedom of Choice Viewpoint,” prepared for theOffIce of Technology Assessment, U.S. Congress,Washington, DC, June 1988. 0

284a. Federation of State Medical Boards of the United

285.

286.

States, Inc., The Exchange (Ft. Worth, TX: Federa-tion of State Medical Boards of the United States,1987).

Ferreira De Santana, C., Goncalves de Lima, O.,D’Albuquerque, I.L., et al., “The Antitumor andToxic Properties of Substances Extracted From theWood of Tabebuia avellandedue,” Rev. Inst. Anti-biot. Univ. Fed. Perrumnbuco Recife 8:89, 1%8.Ferreira De Santana, C., Lins, L.J.P., Asfora, J.J., etal., “Primeiras Observa@es com Eemprego do

89-142 0 - 90 - 10 QL 3

266 ● Unconventional Cancer Treatments

287.

288.

289.

290.

291.

292.

293.

294.

295.

296.

297.

298.

299.

300.

301.

302.

Llapachol em Pacientes Hurnanos Portadores deNeoplasias Malignus,” Revista ab Instituto d eAntibiotics, Recife, 20(1/2) dez. 1980/1.FinlG D.J., Vice President for Professional Educa-tion, American Cancer Society, Atlanta, GA, per-sonal communication, July 1988.Fink, J., Advisory Panel member, InternationalAssociation of Cancer Victors and Friends, SantaBarbara CA, personal communication, 1988.Fink, J.M., Third Opinion: An International Direc-tory to Alternative Therapy Centers for the Treat-ment and Prevention of Cancer (Garden City ParlqNY: Avery Publishing Group, Inc., 1988).Finley, E.B., and Cerklewski, F.L., “Influence ofAscorbic Acid Supplementation on Copper Statusin Young Adult Men,” Am. J. Clin. Nutr. 37:553,1983.Firby, D., “A Renegade Doctor With a CancerCure,” A4acleans, p. 52. March 1,1982.Fishbein, M., “History of Cancer Quackery,”Perspectives in Biology and Medicine 8:139-166,Winter 1965, cited in P.S. Warc$ “History ofHoxsey Treatment,” prepared for the Office ofTechnology Assessment, U.S. Congress, Washing-ton, DC, May 1988.Fisher, A., Exceptional CancerPatients, New Haven,CT, personal communication, January 31, 1990.Fitzgerald, B.F., “A Report to the Senate InterstateCommerce Committee on the Need for Investiga-tion of Cancer Research Organizations,” Congres-sional Record, August 3, 1953, Vol. 99, Part 12,A5350-A5353, (Washington, DC: U.S. Gover-nment Printing Office, 1953).Flavin, T., Supervising Investigator, Office ofProfessional Medical Conduct, New York StiteDepartment of Health, Albany, ~, personal com-munication, October 1988.Fold+ S., and Dombradi, G.A., “lbrnor-Gmvt.hInhibiting Substances of Plant Origin. I. Isolation ofthe Active Principle of Arctium Zappa,” Acta Phys.Chem. 10:91-93, 1964.Forest, W., “AIDS, Cancer Cured by Hyper-Oxygenation,” Health Freedom News 7(5):18-37,1988.Foundation for Alternative Cancer Treatments,“What Is FACI’?” New Yorlq ~, undated.Foundation for Alternative Medicine, “DearFriendof Freedom of Choice in Medicine,” letter, Miami,FL, December 3, 1987.Fox, B.H., “Depressive Symptoms and Risk ofCancer,” JA.MA. 262(9):1231, 1989.Franz, H., “Mistletoe Ixdns and Their A and BChains,” Oncology 43(Suppl. 1):23-34, 1986.Franz, H., “Request for an Impartial Discussion oftheSo-calledMistletoeTherapy,’ ‘Or2cology43(SuppL1):1, 1986.

303.

304.

305.

306.

307.

308.

309.

310.

311.

312.

313.

314.

315.

316.

Fraser, S.S., and Allen, C., “Could Essiac HaltCancer?” Homemaker’s June/July/August, 1977.Free v. Travelers, 551 F. Supp. 554 (D. Md. 1982),as cited in G.P. Monaco and R. Burke, “Insurer asGatekeeper: Handling Claims for Unproven Meth-ods of Medical Management” The Forum 18(4):591-614, Summer 1981.Freimuth, V., University of Maryland, CollegePark, MD, personal communication, December1987.Freimuth, V., “The Public’s Search for Informationon Unorthodox Cancer Treatments: The CIS Expe-rience,” prepared for the OffIce of TechnologyAssessment, U.S. Congms, Washington, DC, Feb-ruary 18, 1988.Freimuth, V. S., Greenberg, R.H., DeWitt, J., et aL,“Covering Cancer: Newspapers and the PublicInterest,” Journal of Communication 34(1):62-72,Winter 1984.Friedman, F., bng Island, NY, personal communi-cation, January 1989.Friedman, F., and Burton, L., “Benign and Invasive-ors Induced in Drosophila by an Inherited‘Iiunor-inducing Factor,” Cancer Res. 16:1059-1061, 1956.Friedman, F., Burton, L., Kaplan, M.L., et aL, “TheEtiology and Development of a Melanotic lbrnor inDrosophila,” Pigment Cell Biology: Proceeding ofthe Fourth Conference on the Biology of NormalandAtypicalPigment Cell Growth, M. Gordon (cd.)(New York NY: Academic Press, 1959).Friedman, F., Burton, L., and Kassel, R., “TheExtraction and Refinement of Two AntitumorSubstances,” Trans. N.X Acad. Sci. Ser. II, 25:29-32,1962.Friedman, F., Burton, L., and Mitchell, H.K.,“Characteristics of an Inherited Timor-inducingFactor in Drosophila melanogaster,” Cancer Res.17:208-214, 1957.Friedman, F., Burton, L., and Mitchell, H.K., “Ali.unor-inducing Factor in Drosophila melanogas-ter,” Ann. N.11 Acad. Sci. 68(2):349- 355, 1957.Friedman, F., Burton, L., and Rottino, A., “Necro-sis Liquefaction and Abso~tion of C3H Mammary‘Ihmors Resulting From Injection of Extracts From‘lhrnor Tissue,” abstract no. 78, Proceedings of theAmerican Assoctition for Cancer Research 6:20,1965.Friedman, F., Kassel, R., Burton, L., et aL, “ARapid (24 Hour) Bioassay for Detection of Humanand Mouse ‘Iiunor Factor,” Proc. Soc. Exp. Biol.Med. 103:16-19, 1960.Friedman, M., National Cancer Institute, NationalInstitutes of Health, U.S. Department of Health andHuman Services, Bethesda, MD, personal commun-ication, 1989.

References .267

317. Fritz, N., “Annotated Hourly Schedule,” dated19779A Cancer Therapy. Results of Fi~ Cases, 4thed. (Bonita, CA: Gerson Institute, 1986).

318. Fritz, N., Gerson Institute, “Progress Report,”typescript, August 1983.

319. Fuks, J.Z., Egorin, M.J., Aisner, J., et al., “Cyclo-phosphamide and Dirnethylsulfoxide in the Treat-ment of Squamous Cell Carcinoma of the Lung.Therapeutic Efficacy, Toxicity and Pharrnacokinet-ics,’ Cancer Chemother. Pharmacol. 6(2):117-120, 1981.

320. Furlong, E., Senior Medical Claims Examiner,CIGNA, Hartford, ~, personal communication,July 1988.

321. Garcia, J., Director, Employee Benefits Division,Aetna Life and Casualty Company, Hartford, ~,personal communication, June 1988.

322. Genesis West (Division of Vitachem InternationalInc.), “Live Cell Therapy,” patient brochure,Redwood City, CA.

323. Geran, R.I., Greenberg, N.H., Macdona14M.M., etal., “Protocols for Screening Chemical Agents andNatural Products Against Animal Thrnors and OtherBiological Systems (3rd cd.),” Cancer Chemother.Reports (Part 3) 3(2):1-103, 1972.

324. Gershanovich, M.L., Danova, L.A., Ivin, B.A., etal., “Results of Clinical Study of Antitumor Actionof Hydrazine Sulfate,” Nutr. Cancer 3(1):7-12,1981.

325. Gerson Institute, “GersonTherapy Center Infonna-tion Sheet,” January 14, 1986.

326. Gerson Institute, “Raw Liver Juice Has BeenDiscontinued,” memo, October 3, 1989.

327. Gerson Institute, “David: Sharing His Experi-ence,” Healing Newsletter 5(2):10-15, 1989.

328. Gerson Institute, “Gerson Therapy,” informationbrochure, undated.

329. Gerson Institute, “Gerson Therapy Center Opens.When Cancer Becomes Incurable by OrthodoxMethods, Perhaps Gerson Therapy is the Answer,”flyer, undated.

330. Gerson Institute, unpublished typescript, undated.331. Gerson, M., “Dietary Considerations in Malignant

Neoplastic Disease,” Rev. Gastroent. 12(6):419-425, 1945.

332. Gerson, M., letter to R.R. Spencer, Chief, NationalCancer Institute, National Institutes of Health, U.S.Department of Health and Human Services, March18, 1947.

333. Gerson, M., “Effects of a Combined DietaryRegimen on Patients With Malignant ‘Ihmors,”Exp. Med. Surg. 7(4):299-317, 1949.

334. Gerson, M., “No Cancer in Normal Metabolism,”translated from Medizinische Klinik 5:175-179,1954.

335. Gerson, M., “Cancer, a Problem of Metabolism,”translated from Medizinische Klinik 49(26):1028-1032,1954.

336. Gerson, M., “TheCureofAdvancedCancerbyDietTherapy: A Summary of 30 Years of ClinicalExperimentation,” Physiol. Chem. Phys. 10:449-464,1978.

337. Gerson, M., A Cancer Therapy. Results of FiftyCases, 4th ed. (Bonita, CA: Gerson Institute, 1986).

338. Ginsberg, M.M., Department of Health Services,County of San Diego, San Diego, CA, letter to J.Z.Yetiv, San Carlos, CA, April 18,1988.

339. Ginsberg, M.M., Thompson, M.A., Peter C.R., etal., “Campylobacter Sepsis Associated With ‘Nu-tritional Therapy’-cidifOti,” M.M.WR. 30(24):294-295,1981.

340. Girard, M., KindaclL D., Dawson, B.A., et al.,“Naphthoquinone Constituents of Tabebuia spe-cies,” J. Nat. Prod. 51:1023-1024, 1988.

341. Glassrnan, J., The Cancer Survivors andHow TheyDid It (New York NY: Dial Press, 1983).

342. Glatthaar, B.E., Hornig, D.H., and Moser, U., “TheRole of Ascorbic Acid in Carcinogenesis,” Adv.Exp. Med. Biol. 206: 357-377, 1986.

343. Gleeson, S., “Private Insurer Coverage and Tech-nology Assessment,” paper presented at the Cover-age and Payment for Drugs and Devices Meetingsponsored by the Food and Drug Law Institute,Washington, DC, September 15,1988.

344. Gleich, R., “My Road to Recovery,” HippocratesNews 9(1):3-4, 1990.

345. Gold, J., “ProposedTreatmento fCancerby Inhibi-tion of Gluconeogenesis,” Oncology 22:185-207,1968.

346. Gold, J., “Inhibition by Hydrazine Sulfate andVarious Hydrazides of In Vivo Growth of Walker256 Intramuscular carcinom~ B-16 MelanoUMurphy-Sturm Lymphosarcoma, and L-121O SolidLeukerni&” Oncology 27:69-80, 1973.

347. Gold, J., “CancerCachexiaandGluconeogenesis,”Ann. NY. Acad. Sci. 230:103-110, 1974.

348. Gold, J., “Inhibition of Gluconeogenesis at thePhosphoenolpyruvate Carboxylcinase and PyruvateCarboxylase Reactions, as a Means of CancerChemotherapy, “ Oncology 29:74-89, 1974.

349. Gold, J., “UseofHydrazineS ulfateinTerminalandPreterminal Cancer Patients: Results of Investiga-tional New Drug (IND) Study in 84 EvaluablePatients,” Oncology 32:1-10, 1975.

350. Gold, J., “Hydrazine Sulfate: A Current Perspec-tive,” Nutr. Cancer 9(2&3):59-66, 1987.

351. Goldin, A., Schepartz, S.A., Venditti, J.M., etal.,’ Historical Development and Current Strategy ofthe National Cancer Institute Drug Developmentprogram,” Methods in Cancer Research, Vol. XVI,

268 ● Unconventional Cancer Treatments

352.

353.

354.

355.

356.

357.

358.

359.

360.

361.

362.

363.

364.

365.

Part A, V.T DeVita, Jr., and H. Busch (eds.) (NewYork, NY: Academic, 1979).Goncalves de Lima, O., Sidney de Barros Coelho,J., D’Albuquerque, I.L., et al., “Antimicrobial andAntitumor Activity of Lawsone in ComparisonWith Lapachol,” Rev. Inst. Antibiot. Univ. Fed.Pernambuco Recife 11:21-26, 1971.Gonzalez, N.J., One Man Alone: An Investigation ofNutrition, Cancer, and Willian Donald Kelley,unpublished manuscript, 1987.Gmzalez, N.J., Physician, New York, NY, personalcommunications, January 31, 1988, and March 10,1988 (letter).Gonzalez, N., “No Toxicity With Coffee Enemas orLaetrile,” (letter), Townsend Letter for Doctors64:496-497, November 1988.Gonzalez, N.J., cited in M. Napoli, “A Classically-trained Doctor Who Uses Nutritionally-based Can-cer Treatments,” HealthFacts 15(130):4-5, 1990.Goodspeed, R. B., Assistant Medical Director, Cor-porate Medical Division, CIGNA Corporation,Hartford, CT, personal communication, June 1988.Gorrnan, J.R., and bcke, S.E., “Neural, Endocrine,and Immune Interactions,” The ComprehensiveTextbook of Psychiatry, 5th cd., H.I. Kaplan, andB.J. Sadock (eds.) (Baltimore, MD: William andWikins, 1989).Greenberg, N. H., Developmental Therapeutics Pro-gram, Division of Cancer Treatment, NationalCancer Institute, National Institutes of Health, U.S.Department of Health and Human Services, Memoto J.A.R. Mead, Acting Associate Director, Devel-opmental Therapeutics Program, Division of Can-cer Treatment, National Cancer Institute, November1, 1983.Greenberg, N.H., National Cancer Jnstitute, Memoto J.M. Venditti, National Cancer Institute, March 1,1985.Greenwald, P., “Principles of Cancer Prevention:Diet and Nutrition,” Cancer. Principles and Prac-tice of Oncology, 3rd cd., V.T. DeVita, Jr., S.Hellrnan, and S.A. Rosenberg (eds.) (Philadelphia,PA: J.B. Lippincott, 1989).Griffin, G.E., World Without Cancer: The Story ofVitamin B17(Thousand Oaks, CA: American Medi~1975).Grossarth-Matice~ R., Schmidt, P., Vetter, H., etal., “Psychotherapy Research in Oncology,”Health Care and Human Behaviour, A. Steptoe andA. Mathews (eds.) (I_xmdon, England: Academic,1984).Grotz, W., ECHX12, Delano, MN, personal com-munication, April 29, 1988.Guthrie, J.R., Director, The Health Resource, Con-way, AR, personal communications, 1987-1988.

366.

367.

368.

369.

370.

371.

372.

373.

374.

375.

376.

377.

378.

379.

380.

381.

Guthrie, J.R., “Personal Narrative,” prepared forthe Office of Technology Assessment, U.S. Con-gress, Washington, DC, undated.Hajto, T, “Immunomodulatory Effects of Iscador:A Viscum album Preparation,” Oncology 43(Suppl1):51-65, 1986.Hajto, T., Hostanska, K., “An Investigation of theAbility of Viscum album-activated Granuhxytes toRegulate Natural Killer Cells h Vivo,” ClinicalTrials J. 23(6):345-358, 1986.Hajto, T., and Lanzrein, C., “Natural Killer andAntibodydependent Cell- mediated CytotoxicityActivities and Large Granular Lymphocyte Fre-quencies in Viscum album-treated Breast CancerPatients,” Oncology 43:93-97, 1986.Hall, H.H., “Hypnosis and the Immune System: AReview With Implications for Cancer and thePsychology of Hea.ling,’’Am.J. Clin.Hypn. 25(2-3):92-103, 1982-83.Halstead, B., ‘‘The Halstead Cancer Battle: A LegalEpilogue,” Townsend Letter for Doctors 38:157,188-190, June 1986.Halstead, B., “The Lynching of a Doctor: HalsteadReceives a Draconian Sentence,” Tmnsendbtterfor Doctors 38:157, June 1986.Hammond, S.L., “An Examination of the PublicEducation Efforts of Three Mainstream CancerOrganizations,’ prepared for the Office of Technol-ogy Assessment, U.S. Congress, Washington, DC,March 1, 1988.Hamprecht, K., Handgretinger, R., Voetsch, W., etal., “Mediation of Human NK-activity by Compo-nents in Extracts of Viscum album, ’ Int. J. Immuno-pharrnacol. 9(2):199-209, 1987.Han, J., “Traditional Chinese Medicine and theSearch for New Antineoplastic Drugs,” J. Ethno-pharmacol. 24:1-17, 1988.Hans Nieper Foundation, Inc., News, Issue No. 1,August 1986.Hans Nieper Foundation, Inc., Year End Synopsis,Jackson, WY, 1986.Hans Nieper Foundation, Inc., “Year End Synop-sis,” letter, San Juan Capistrano, CA, 1986.Hans Nieper Foundation, Inc., “Hans Nieper Foun-dation, Inc.,” unpublished mimeograph, San JuanCapistrano, CA, undated.Harnly, M.H., Burton, L., Friedman, F., et al.,“lhmor Induction in Drosophila melanogaster byInjection of e(l l)tuLarvalFluid,” Science 120:225-227, 1954.Harris, A.T., “Terminal Cases of MalignancyTreated with Laetrile,” A New Approach to theConquest of Cancer, Rheumatic and Heart Dis-eases, H.H. Beard (cd.) (New York NY: PageantPress, 1962).

References ● 269

382.

383.

384.

385.

386.

387.

388.

389.

390.391.

392.

393.

394.

395.

HartWell, J.L., “Plants Used Against Cancer. ASurvey,” LZoydia 30(4):379-436, 1967, followedby 10 additional installments in the same journal,ending with LZoydia 34(4):386-425, 1971.Hartwell, J.L., memo to R.A. Tjalma, AssistantDirector, National Cancer Institute, National Insti-tutes of Health, U.S. Department of Health andHuman Services, July 25, 1975.Hartwell, J.L., “Types of Anticancer Agents Iso-latedFrom Plants,” Cancer Treat. Rep. 60(8):1031-1067, 1976.Hashimoto, K., Koga, T, Shintorni, Y., et al., “TheAnticancer Effect of Antineoplaston AIO on HumanBreast Cancer Serially Transplanted to AthymicMice,” J. JapanSoc. Cancer Ther. 25(1):1-5, 1990.Hassauer, W., Gutsch, J., and Burkhardt, R., “Wel-che Erfolgsaussichten Bietet die IscadortherapieBeim Fortgeschrittenen Ovarialkarzinom?’ OnkoZ-ogie 2:28-36, 1979.Haught, S.J., Cancer? Think Curable. The GersonTherapy (Bonita, CA: Gerson Institute, 1983)(introduction and footnotes by N. Fritz), (previoustitle: Has Dr. Max Gerson a True Cancer Cure?(Ixmdon, England: London Press, 1962)).Health and Welfare Canada, Health ProtectionBranch, “Issues: Essiac—An Ineffective CancerTreatment,” typescript, February 7, 1989.Health Freedom News, “Active Chapters,” HealthFreedom News 9(4):16, 1990.Healthexcel, Winthrop, WA, brochure, 1986.Henderson, I. C., “Point/Counterpoint: NCI Clini-cal Alert Policy: Shouldn’t We See the White FlagBefore We Cry Victory?” J. Natl. Cancer Inst.82(2):103-109, 1990.Henderson, I. W.D., Director, Bureau of HumanPrescription Drugs, Health Protection Branch,Health and Welfare Canada, Vanier, Ontario, letterto J.W. Meakin, Executive Director, Ontario CancerTreatment and Research Foundation, Toronto, On-tario, November 19, 1982.Hendry, L.B., and Muldoon, T.G., “Actions of anEndogenous Antitumorigenic Agent on Mammary‘Ihmor Development and Modeling Analysis of ItsCapacity for Interacting with DNA,” J. SteroidBiochem. 30(106): 325-328, 1988.Henne v. Mutual of Omaha, Civ. No. 81-1398(D.D.C. 1983), as cited in G.P. Monaco, and R.L.Burke, “Insurer as Gatekeeper - Part Two: PolicyObstacles in Unproven Methods Litigation,” TheForum 20(3):400-417, Spring 1985.Henney, J.E., ‘Unproven Methods of Cancer Treat-ment,” Cancer: Principles and Practice of Oncol-ogy, V.T DeVita, Jr., S. Hellman, and S.A.Rosenberg (eds.) (Philadelphia, PA: J.B. Lippin-COtt, 1985).

396.

397.

398.

399.

400.

401.

402.

403.

404.

405.

406.

407.

408.

409.

410.

411.

412.

Herbert, V., “The Cult of Cyanide: PromotingPoison for Profit,” Am. J. Clin. Nutr. 32:1121-1158, 1979.Herdrnan, R. C., Assistant Director, OffIce of Tech-nology Assessment, U.S. Congress, letters to L.Burton, July 13, 1987, June 1, 1989, and December13, 1989.Hernandez, M., “Man Pleads Guilty in UnlicensedTreatment of Cancer Patient,” The Arizona DailyStar p. 4B, January 31, 1990.Herson, J., “Statistical Aspects in the Design andAnalysis of Phase II Clinical Trials,” CancerClinical Trials: Methods and Practice, M.E. Buyse,M.J. Staquet, and R.J. Sylvester (eds.) (Oxfor4England: Oxford University Press, 1984).Hildenbrand, G., letter to “Friends of Gerson,”Healing Newsletter, No. 20 & 21, p. 11, July-October, 1987.Hildenbrand, G., Advisory Panel member, GersonInstitute, personal communications, June 15, 1988,July 1988, 1989, and 1990.Hildenbrand, G., Gerson Institute, “Procedure andCriteria for Selection of Best Cases,” memo to Drs.Pelton, Ortuno, and Rogers, Gerson Institute, un-dated.Hildenbrand, G., and Blake, M. (eds.), “The GersonDiet Therapy as Represented by the Peer ReviewedLiterature Referenced in the Cumulated IndexA4edicus,” typescript obtained horn the GersonInstitute, Boni@ CA, July 1986.Hill, G.J., Shine, YE., Hill, H.Z., et al., “Failure ofAmygdalin to Arrest B16 Melanoma and BW5147AKR Leukemia, ’ Cancer Res. 36:2102-2107,1976.Hippocrates Health Institute, West Pahn Beach, FL,brochure, undated.Hoffman, B., “Current Issues in Cancer Survivor-ship,” Oncology 3(7):85-88, 1989.Hoffman, F.A., “Macro- and Micronutrient Re-quirements of Cancer Patients,” Clinics in Oncol-0~ 5(2):337-353, 1986.Holland, J. C., “Why Patients Seek Unproven Can-cer Remedies: A Psychological Perspective,” CA32(1):3-7, 1982.Holleb, A., “Editorial: The American Cancer Soci-ety at 75 Years,” CA 38(1):2, 1988.Holohan, T, “Referral by Default,” J.A.h4A.257(12):164142, 1987.Holohan, T., Medicine Staff, Food and Drug Ad-ministration, U.S. Department of Health and HumanServices, Rocldle, MD, personal communication,October 24, 1988.Holoweiko, M., “Insurance-Fraud Cops Have aWhole New Set of Teeth,” Medical Economics65:153-170, March 1988.

270 ● Unconventional Cancer Treatnwnts

413.

414.

415.

416.

417.

418.

419.

420.

421.

422.

423.

424.

425.

426.

427.

428.

429.

Holtskog, R., Sandvig, K., and Olsnes, S., “Charac-terization of a Toxic bctin in Iscador, a MistletoePreparation With Alleged Cancerostatic Proper-ties,” Oncology 45:172-179, 1988.Holtz, J., Public Affairs Officer, Office of theInspector General, U.S. Department of Health andHuman Services, Washington, DC, personal com-munication, September 1988.Hoshi, A., Ikekawa, X, - Y, et al., “AntitumorActivity of Berberrubine Derivatives,” Jpn. J.Cancer Res. (Gann) 67:321-325, 1976.Houston, R. G., Repression and Reform in theEvaluation ofAlternative Cancer Therapies (Wash-ington, D.C!.: Projed Cure, 1989).Houts, P. S., Yasko, J., Kahn, S.B., et al., “UnmetPsychological, Social, and Economic Needs ofPersons With Cancer in Pennsylvania,” Cancer58:2355-61, 1986.Hoxsey, H.M., You Don’t Have to Die (New YorkNY: Milestone Books, 1956).Hufford, D.J., “Cultural and Social Perspectives onUnorthodox Cancer Treatments,” contract report toOffIce of Technology Assessment, U.S Congress,February 1988.Hufford, D.J., “Health Food Store Survey onAlternative Cancer Treatment Information,” pre-pared for the Office of Technology Assessment,U.S. Congress, Washington, DC, June 1988.Htiord, D.J., “Selected Unorthodox Cancer Prac-titioners,” contract report to OMce of TechnologyAssessment, U.S. Congress, 1988.Hundsdorfer, Gabriele, German Government Offi-cial, letter, November 1989.Hwemann, F., The Anthroposophical Approach toMedicine: An Outline of a Spiritual ScientificallyOriented Medicine, VOI 1, newly edited and revisedby O. Wolff (Spring Valley, NY: The Anthroposo-phic Press, 1982).Hussar, D.A., “New Drugs 1983,” Am Pharrn. NS24(3):2340, March 1984.Hutchinson, C., Immunology Researching Centre,Inc., letter and comments, typescript, 18 pp., June18,1987.Hutchinson, C., MI’ patient representative, personalcommunications, September 1987 and May 1988.Hutchison, D.J., Experimental Chemotherapy, Me-morial Sloan-Kettering Cancer Center, Rye, N,personal communication, September 26, 1988 andMarch 1989.Immuno-Augmentative Therapy Centre, Ltd. Dr.Luwrence Burton’s LAT: Irnmuno-Augrnentative Ther-apy, Cancer Research and Treatment brochure,March 1988.Imrnuno-Augmentative Therapy Centre, Ltd. l..:Immuno-Augmentative Therapy, Cancer Researchand Treatment brochure, March 1988.

430.

431.

432.

433.

434.

435.

436.

437.

438.

439.

440.

441.

442.

443.

Imrnuno-AugmentativeThempy Centre,Ltd, “IAX:Irnmuno-Augmentative Therapy,” brochwe, ~-dated.Immuno-Augmentative Therapy Patients Associa-tion, form letter enclosed with letter to LWI?Amembers, signed by D. Weiwel and F. Weiwel,October 29,1987.Immunology Research Foundation, Inc., “herComplement Fraction Recovery Method and Prod-uct,” Patent #4076701, February 28,1978.Immunology Research Foundation, Inc., “Deblock-ing Protein Fraction Recovery Method and Prod-uct,” Patent #4082732, April 4,1978.Immunology Research Foundation, Jnc., “BlockingProtein Fraction Recovery Method and Product,”Patent #4082733, April 4, 1978.Immunology Research Foundation, Inc., “BlockingProtein Fractions Recovery Methods and Prod-ucts,” Patent #4196121, April 1, 1980.Immunology Research Foundation, Inc., “Prol AFraction Recovery Method and Product,” Patent##1199497, April 22, 1980.In re Cole, 476 A.2d 836 (N.J. 1984), as cited inR.D. Schwartz, and R.L. Burke, “bgal Constraintson the Availability of Unorthodox Cancer Treat-ments: Consumer Protection Viewpoint,” preparedfor the Office of Technology Assessment, U.S.Congress, Washington, DC, April 1988.In re Har~ W. Graham and Ellen L. Graham, No.CS-8344-8345 Del. Sup. Ct., Muncie, Ind. (1984),as cited in R.D. Schwartz, and R.L. Burke, “I_egalConstraints on the Availability of UnorthodoxCancer Treatments: Consumer Protection View-point,” prepared for the OfIice of TechnologyAssessment, U.S. Congress, Washington, DC, April1988.In re Hofiauer, 419 N.Y.2d at 940-41 as cited inG.M. Lerner, and J.E. Weeks, “The Laetrile PowerPlay in Drug Marketing,” Ham2ine law Review3(1):1-50, 1980.In re Hofiauer, 47 N.Y2d 648,393 N.E. 2d 1009,419 N.YS.2d 936 (1979), as cited in Ohio StateLaw Review, “The Uncertain Application of theRight of Privacy in Personal Medical Decisions:The Laet.rile Cases,” Ohio State Law Journal42(2):523-550, 1981.In re Quinian, 70 N.J. 10,355 A2d 647, cert. dkniedsub. sore. Garger v. New Jersey 429 U.S. 922(1976) overruled inpart, In re Conroy 98 N.J. 321,486, A.2d 1209 (1985).In the Matter of General Nutrition, Inc., UnitedStates of America Before Federal Trade Commis-sion, Docket No. 9175, February 2, 1989.In the Matter of the Complaint Against Ronuld andPamela McCaa and &b/a Lighthouse, P.S. Docket

References .271

444.

445.

446.

447.

448.

449.

450.

451.

452.453.

454.

455.

456.

457.

458.

459.

460.

No. 34/168, July 28, 1989; Cease-and-Desist OrderNo. CD-2647, July 28,1989.In the Matter of Virginia C. Livingston, M.D., U.S.Department of Health and Human Services, SocialSecurity Administration, Docket No. HIX-OOO-90-0213, Decision, September 16,1987.Ingelfinger, F.J., “Cancer! Alarm! Cancer!” N.Engl. J. Med. 293(25):1319-1320, 1975.Institute of Medicine, Committee for EvaluatingMedical Technologies in Use, Assessing MedicalTechnologies (Washington, DC: National AcademyPress, 1985).Institute of Medicine, Council on Health CareTechnology, Medical Technology Assessment Di-rectory (Washington, DC: National Academy Press,1988).Intergovernmental Health Policy Project, “Focuson State Oversight and Regulation of Physicians,”Intergovernmental Health Policy Project Number22 (Washington, DC: September 1988).International Association of Cancer Victors andFriends, “Essiac Information,” typescript distrib-uted by the International Association of CancerVictors and Friends, Victoria, British Columbi~undated.Istre, G.R., Kreiss, K., Hopkins, R.S., et al., “AnOutbreak of Amebiasis Spread by Colonic Iniga-tion at a Chiropractic Clinic,” N. Eng/. J. Med.307(6):339-342, 1982.Itokawa, H., Watanabe, K., Mihara, K., et al.,“Screening Test for Antitumor M.ivity of CrudeDrugs (2),” ShoyakugakuZasshi 36:145-149, 1982.Ivy v. Katzenbach, 351 F.2d 32 (7th Cir. 1965).Jackson, C., Hans NieperFoundation, Inc., SanJuanCapistrano, CA, typescript, May 20, 1987.Jacob, J., ‘lMly, S.B., and Chapman, B., “Hypo-natrernia and Perforation of the Bowel Following aSeries of Water Enemas: A Case Report in a14-month-oldInfant,” CZin. Pediatr. (PhiZa.) 15:776-778,1976.Jacob, M., Foundation for Alternative Medicine,Cancer Control Society Convention tape, July 1987.Jacob, M., Alliance for Alternative Medicine, Lib-erty Lake, WA, personal communication, Septem-ber 13, 1989.Jacobs, C., and Dwyer, J.T, “Vegetarian Children:Appropriate and Inappropriate Diets,” Am. J. Clin.Nutr. 48(3 Suppl.):811-818, 1988.Jaffe, R., Abady & Jaffe, New York NY, personalcommunication, May 7, 1990.James, N., Reed, A., and Sikorz K., “DietaryTherapy For Cancer-An Objective Assessment,”typescript, undated.Jamison, R.N., Burish, TG., and Wallston, K.A.,“Psychogenic Factors in Predicting Survival of

461.

462.

463.

464.

465.

466.

467.

468.

469.

470.

471.

472.

473.

474.

475.

Breast Cancer Patients,” J. Clin. Oncol. 5(5):768-772,1987.Jemmott, J.B., “Psychoneuroimmunology. The NewFrontier, ’’American Behavioral Scientist 28(4):497-509,1985.Johnson v. District 2 Marine Engineers BeneficialAssoctition, 857 F.2d 514 @th Cir. 1988) as citedin Filary v. General American Ll~e Ins. Co., 711F. Supp. 528 (D.Ariz. 1989).Johnston, W.’E, Assistant Postmaster General, Gov-ernment Relations Department, U.S. Postal Service,Washington, DC, personal communication, March28, 1990.Jordan, E., and Wagner, H., “Structure and Proper-ties of Polysaccharides From Viscum album (L.),”Oncology 43 (suppl. 1):8-15, 1986.Journal of the American Medical Association,editorial, “Gerson’s Cancer Treatment,” J.A.MA.132(11):645-646, 1946.Journal of the American Medical Association,“Diagnostic and Therapeutic Technology Assess-ment (DATI’A): Whole-Body Hyperthermia Treat-ment of Cancer,” JAM.A. 251(2):272, 1984.Journal of the American Medical Association,“Diagnostic and Therapeutic Technology Assess-ment (IXITA): Immunoaugmentative Therapy,’J.A.MA. 259(23):3477-3478, 1988.Kassel, R., Burton, L., and Friedman, F., “Utiliza-tion of an Induced Drosophila Melanoma in theStudy of Mammalian Neoplasia, “ Ann. N.X Acad.Sci. 1OO(II):791-816, 1963.Kassel, R., Burton, L., Friedman, F., et al., “Carcin-ogenic Action of Refined 3hmor Factor Isolatedfrom Mouse I.akemia Tissue,” Proc. Soc. Exp.Biol. Med. 101(2):201-204, 1959.Kassel, R., Burton, L., Friedman, F., et al., “Syner-gistic Action of Two Refined Leukemic TissueExtracts in Oncolysis of Spontaneous ‘Ibmors,”Transactions of the N.11 Academy of Sciences Ser.II, 25:39-44. 1962.Kellen, J.A., Kolin, A., and Acevedo,H.F., “Effectsof Antibodies to Choriogonadotropin in MalignantGrowth. L Rat3230AC Mammary A&nocarcinW”Cancer 49(11):2300-2304, 1982.Kelley, W.D., One Answer to Cancer. An Ecologi-cal Approach to the Success@ Treatment of Malig-nancy (Wtileld, KS: Wedgestone Press, 1%9).Kern, K.A., and Norton, J.A., “Cancer Cachexia,”Journal ofParenteralandEnteralNutrition 12(3):286-298,1988.Kessler, D.A, “The Regulation of InvestigationalDrugs,” N. Engl. J. Med. 320(5):281-288, 1989.Khwaj~ TA., Dias, C.B., and Pentacost, S., “Re-cent Studies on the Anticancer Activities of Mistle-toe (Viscum album) and Its Alkaloids,” Oncology43(suppl. 1):42-50, 1986.

272 ● Unconventional Cancer Treatments

476.

477.

478.

479.

480.

481.

482.

483.

484.

485.

486.

487.

488.

489.

490.

491.

492.

493.

Kiecolt-Glaser, J.K., and Glaser, R., “PsychosocialModerators of Immune Function,” Ann. Behav.Med. 9:16, 1987.King, F.X., Rudo~ Steiner and Holistic Medicine(York Beach, ME: Nicolas-Hays, Inc., 1986).Kirchner, S.G., BuckSpan, G. S., O’Neill, J.A., et al.,“Detergent Enema: A Cause of Caustic Colitis,”Pediatr. Radiol. 6:141-146, 1977.Kjaer, M., “Treatment of Metastasizing RenalCancer With Mistletoe. A Phase II Investigation,”Ugeskr Laeger 150:1923-1928, 1988.Klein, A., Bureau of Human Prescription Drugs,Health Protection Branch, Health and WelfareCanada, Vanier, Ontario, letter, October 19, 1988.Kochi, M., Isono, N., Niwayarna, M., et al.,“Antitumor Activity of a Benzaldehyde Deriva-tive,” Cancer Treat. Rep. 69(5):533-537, 1985.Kochi, M., Takeuchi, S., Mizutani, T, et al.,“Antitumor Activity of Benzaldehyde,” CancerTreat. Rep. 64(1):21-23, 1980.Kohler, J., and Kohler, M.A., Healing MiraclesFrom Macrobiotics (West Nyack, NY: Parker,1979).Kohn, R., Managing Director, Advisory Services(Clinical & General) Limited, Ixmdon, England,letter to M. Finotto, M.D., Farchemia SpA, Tre-viglio (BG), Italy, December 5, 1986.Konopa, J., Jereczek, E., Matuszkiewicz, A., et al.,‘‘Screening of Antitumor Substances FromPlants,” Arch. Immunol. Ther. Exp. 15:129, 1957.Kossl, T., Vice President and General Counsel,MetPath Inc., letter to G. Solan, Office of Technol-ogy Assessment, U.S. Congress, March 30, 1989.Koster, M., and David, G.K., “Reversible SevereHypertension Due to Licorice Ingestion,’ N. Engl.J. Med. 278(25):1381-1383, 1968.Kripke, M.L,, ‘‘Immunoregulation of Carcinogene-sis: Past, Present, and Future,” J. NatZ. Cancer Inst.80(10):722-727, 1988.Kuhnau, W.W., “Dr. Kuhnau on ‘What You ShouldKnow About Live-cell Therapy,’ “ Cancer Victors’J. 21(314):7-8, 1987.Kuhnau, W.W., and Culbert, M.L., “Live CellTherapy,” Twnsendtitterfor Doctors 67/68:118-119, February/March 1989.Kuhnau, W.W., and Rodriguez, R., “First Prelimi-nary Communication on the Efficacy of EmbryonicCells from Shark in Human Therapy,” TownsendLetter for Doctors 63:41 1412, October 1988.Kunst, L., and Ladas, H. S., “Radiation, FreeRadicals, Lipid Peroxidation and Trienic Conju-gated Fatty Acids,” unpublished manuscript, No-vember 20, 1986.Kunst, L., and Ladas, H. S., ‘Testing the Usefulnessof Twin Formation Theory: The Twopherols and

494.

495.

496.

497.

498.

499.

500.

501.

502.

503.

504.

505.

506.

507.

508.

509.

5100

511.

512.

Vha.mi.n D,” unpublished manuscript, November20,1986.Kunst, L., Ladas, H.S., and van Kampen, F.A.,“Cancer Chemotherapy and the Lipids,” unpub-lished manuscript, 1986f7.Kupchan, S.M., and Karim, A., “llunor Inhibitors.114. Aloe Emodin: Antileukemic Principle IsolatedFrom Rhamnusjiangula,” Lloydia 39;223, 1976.Kupsinel, R. (cd.), “An Open Rebuttal to theJournal of the American Medical Association,”Health Consciousness 7(4):5-9, 1986.Kupsinel, R., “The American Quack Association:Quality Care With Kindness Conference,” TheTownsend Letter for Doctors 47:121, May 1987.Kupsinel, R., Letter to readers, Health Conscious-ness 8(5):7, 1987.Kushi Foundation, ‘‘Biography of Michio Kushi,”typescript, undated.Kushi Institute, “Macrobiotics. Standard Dietaryand Way of Life Suggestions for Persons Living ina Temperate Climate,” pamphlet, 1977.Kushi Institute, “The Kushi Institute. World Mac-robiotic Educational Center for a Healthy, PeacefulWorld,” brochure, Brookline, MA, undated.Kushi, L. H., letter to H. Sheehan, American CancerSociety, March 3, 1988.Kushi, L.H., “Foreward,” Doctors Look at Macro-biotics, E. Esko (cd.) (New York, NY: JapanPublications, 1988).Kushi, M., “A Nutritional Overview of the Macro-biotic Diet,” typescript, December 19, 1983.Kushi, M., “Standard Macrobiotic Dietary Prac-tice,” typescript, Brookline, MA: The Kushi Foun-dation and the East West Foundation, 1984.Kushi, M., Kushi Institute, Brookline, MA, letter,August 10, 1988.Kushi, M., “Introduction,’ Doctors Look at il4ac-robiotics, E. Esko (cd.) (New York, NY: JapanPublications, 1988).Kushi, M., and the East West Foundation, TheMacrobiotic Approach to Cancer. TmardPrevent-ing and Controlling Cancer with Diet and Lifestyle(Wayne, NJ: Avery Publishing Group, 1982).Kushi, M., and Jack A., The Cancer PreventionDiet. Michio Kushi’s Nutritional Blueprint for thePrevention and Relief of Disease (New York, NY:St. Martin’s Press, 1983).Kushner, R., Alternatives: New Developments in theWar on Breast Cancer (New York, NY: WarnerBooks, 1984).Kuttan, G., Vasudevan, D.M., and Kuttan, R.,‘‘Isolation and Identification of a lhmour ReducingComponent From Mistletoe Extract (Iscador),”Cancer Lett. 41:307-314, 1988.Ladas, H.S., “Antineoplastons in Cancer Patientswith Five Year Followup,” Townsend Letter for

References ● 273

513.

514.

515.

516.

517.

518.

519.

520.

521.

522.

523.

524.

525.

526.

527.

528.

Doctors 67/68:1, February/March 1988.Ladas, H. S., “The Potential of Selenium in theTreatment of Cancer,’ J. Holistic Med. 4:145-156,1989.

Lan~ “CellThempySuspend@’ ’Lancetii(8557):5O3,1987.Lancet, “Vitamin B12 and Seaweed,” Lanceti(8631):242-243, January 30, 1988.Lang, A., “The Disease of Information Processing.An Interview with Stanislaw R. Burzynski, M.D.,Ph.D.,” Townsend Letter for Doctors 71:292-296,June 1989.Lange, P.H., Ha.kala, TR., and Fraley, E.E., “Sup-pression of Antitumor Lymphocyte Mediated Cyto-toxicity by Human Chorionic Gonadotropins,” J.Urol. 115:95-98, 1976.Larrick, G.P., “Public Warning Against HoxseyCancer Treatment,” Consumer Reports 21:303,1956.Laster W.R., Jr., and Schabel, F.M., Jr., “Experi-mental Studies of theAntitumorActivity of ArnygdalinMF (NSC-15780) Alone and In Combination WithBeta-glucosidase (NSC-128056),” C a n c e r Che-rnother. Rep., Part I, 59:951-965, 1975.Lawrence Review of Natural Products, Chaparral,5(8), August 1984.Lawrence Review of Natural Products, monographon Taheebo, 1986.kchner, P., “The Role of a Modified GersonTherapy in the Treatment of Cancer,” typescript,Second Department of Surgery, Landeskranken-haus, Graz, Austria, 1987.Lederberg, M. S., and Holland, J. C., “Psycho-Oncology,” Comprehensive Textbook of Psychia-try, 5th cd., H.I. Kaplan, and B.J. Sadock (eds.)(Baltimore, MD: Williams and Wilkins, 1989).hrner, A.F., Burzynski, S.R., and Hendry, L. B.,‘‘3-Phenylacetylamin o-2,6-pipendinedione, A Nat-urally-occuring Peptide Analogue with ApparentAntineoplastic Activity, May Bind to DNA,”Drugs Exp. Clin. Res. 12 (Suppl. 1):47, 1986.I.xxner, G. M., and Weeks, J. E., “The Laetrile PowerPlay in Drug Marketing,” Hamline Law Review3(1):1-50, 1980.Ironer, G.M., and Weeks, J. E., Hamline LawReview 3:3940, 1980, as cited in M.S. Evers,“Legal Constraints on the Availability of Unortho-dox Cancer Treatments: Freedom of Choice View-point,” prepared for the Office of TechnologyAssessment, U.S. Congress, 1988.Lerner, H.J., and Regelson, W., “Clinical Trial ofHydrazine Sulfate in Solid Tumors,” Cancer Treat.Rep. 60(7):959-960, 1976.Lerner, M., “The Role of Autonomous CancerSelf-Help Groups as a ‘Third Force’ in the Develop-ment of New Perspectives on Health Promotion,

529.

530.

531.

532.

533.

534.

535.

536.

537.

538.

539.

540.

541.

542.

543.

544.

Conventional Cancer Treatments and Complemen-tary Systems of Cancer Therapy and Self-Care,”paper presented at the World Health OrganizationConference on Health Promotion and ChronicIllness, Bad Honnef, Germany, June 1987.hrner, M., “Toward a Framework for the Analysisof Unconventional Cancer Therapies, ’ contractreport to Office of Technology Assessment, U.S.Congress, typescript, February 1988.brner, M., “Toward a Framework for the Analysisof Unconventional Cancer Treatments, ’ contractreport to Office of Technology Assessment, U.S.Congress, April 1988.Ixxner, M., Integral Cancer Therapies (Bolinas,CA: Commonweal, photocopied, 1989).Ikrner, M., and Remen, R., “Tradecraft of theCommonweal Cancer Help Program,” Advances4(3):11-25, 1987.Leroi, R., “Viscum aZbum Therapy of Cancer,”Brit. Homeopath. J. 67:167-184, 1978.Leroi, R., “Fundamentals of Mistletoe Therapy,”Krebsgeschehen 5:145-146, 1979.I.xxoi, R., “Introduction,” Annual Report of theSociety for Cancer Research, Arlesheim, Switzer-land, 1986.Leroi, R., ‘‘The Mistletoe Preparation Iscador(R) inClinical Use. Clinical Observations,” reprint fromDie Mistel in der Krebsbehandlung, O. Wolff (cd.),pamphlet, Society for Cancer Research, Arlesheirn,Switzerland, 1987.hShan, L. L., Cancer as a Turning Point (NewYork, NY: E.P. Dutton, 1989).I_Ahan, L.L., New York NY, letter, February 19,1990.JA3han, L. L., You Can Fight for Your Life. Emo-tional Factors in the Causation of Cancer (NewYork, NY: M. Evans, 1977).hvi, J., Department of Oncology, Royal NorthShore Hospital, Sydney, Australia, personal com-munication, July 1988.Levi, J.A., Aroney, R. S., Woods, R.L., et al., “ADouble-blind Randomised Evaluation of AscorbicAcid and Placebo in Advanced Adenocarcinoma ofthe Colon and Rectum,” (protocol for evaluation)typescript, Department of Oncology, Royal NorthShore Hospital, Sydney, Australia, undated.Ixwy, S. M., “Behavioral Risk Factors and HostVulnerability,” Psychological, Neuropsychiatric,and Substances Abuse Aspects ofAIDS, T.P. Bridge,et al. (eds.) (New York NY: Raven, 1988).Ixwy, S.M., Lee, J., Bagley, C., et al., “SurvivalHazards Analysis in First Recurrent Breast CancerPatients: Seven-Year Follow-Up,’ Psychosom. Med.50:520-528, 1988.Lewis, B., Advisory Panel member, The Perma-nence Medical Group, letter, April 27, 1990.

89-142 0 - 90 - 11 QL 3

274 ● Unconventional Cancer Treatments

545.

546.

547.

548.

549.

550.

551.

552.

553.

554.

555.

556.

557.

558.

559.

560.

kwis, W.H., and Elvin-Lewis, M.P.F., MedicalBotany: Plants Affecting Man’s Health (New YorkNY: John Wiley and Sons, 1977).Liau, M. C., Szopa, M., Burzynski, B., et al.,“Chemo-surveillance: A Novel Concept of theNatural Defense Mechanism Against Cancer,”Drugs Exp. Clin. Res. 8(Suppl. 1):71-76, 1987.Libercci, W., Office of Investigations, Office of theInspector General, U.S. Department of Health andHuman Services, Washington, DC, personal com-munication, January 18, 1989.Lieberman Research, Inc., ‘A Basic Study of PublicAttitudes Towards Cancer and Cancer Tests,”prepared for the American Cancer Society, NewYork, NY, February 1980.Linderrnan, L., “Finding a Magic Bullet,” Pent-house, p. 106, July 1989.Lindner, L., “Beyond Brown Rice. The New,Improved Macrobiotic Diet,” Am. Health 7(4):71,1988.Ling, G.N., “The Association-Induction Hypothe-sis,” Agressologie 24(7):293-302, 1983.Link, J., Chairman of the Board, IAT Patients’Association, Kalamazoo, MI, personal communica-tion, September 19, 1988.Link, J., Chairman of the Board, L4T Patients’Association, Kalamazoo, MI, personal communica-tion, January 5, 1989.Linkous, R., Food and Drug Administration, U.S.Department of Health and Human Sewices, Rock-ville, MD, personal communication, September 27,1988.Linus Pauling Institute of Science and Medicine,“Abrupt Termination of High Daily Intake ofVitamin C: The Rebound Effect,” The LinusPauling Institute of Science andllledicine Newslet-ter 2(7), Spring/Summer 1985.Linus Pauling hstitute of Science and Medicine,“A Cancer Case History,” The Linus PaulingInstitute of Science and Medicine Newsletter 2(8),Winter 1985-1986.Linus Pauling Institute of Science and Medicine,“GeneralRecommendations forThkingLargeAmountsof Vitamin C,’ mimeograph, Palo Alto, CA,undated.Linus Pauling Institute of Science and Medicine,cover letter to information packet on vitamin Ctreatments for cancer, Palo Alto, CA, undated.Livingston v. Department of Health and HumanServices, Social Security Administration, DocketNo. HIX-000-90-0213, Decision, September 16,1987.Livingston, A. M., Wuerthele-Casp6 Livingston, V.,Alexander-Jackson, E., et al., “Toxic FractionsObtained From Tumor Isolates and Related Clinical

561.

562.

563.

564.

565.

566.

567.

568.

569.

570.

571.

572.

573.

574.

575.

576.

Implications,’ Ann. N.11 Acad. Sci. 174(2):675-689, 1970.Livingston-Wheeler, V,C., “The Role of Nutritionin the Immunotherapy of Cancer, ’ J. lnt. Acad.Prev. Med. 5(2):54-75, 1979.Livingston-Wheeler, V., “Method for Preparing aPurified Extraction Residue Fraction and Its Use inStimulating the Immune Response,” U.S. PatentNo. 4,410,510, October 18, 1983.Livingston-Wheeler, V., and Addeo, E. G., TheConquest of Cancer: Vaccines andDiet (New YorkNY: Franklin Watts, 1984).bcke, S.E., and German, J.R., “Behavior andhmnunity,” The Comprehensive Textbook of Psy-chiatry, 5th cd., H.I. Kaplan, and B.J. Sadock (eds.)(Baltimore, MD: William and Wilkins, 1989).Los Angeles Herald Examiner, cited in G. Null andL. Steinman, “The Vendetta Against Dr. Burton,”Penthouse, p. 37, March 1986.Ixm Harris and Associates, “Health Informationand the Use of Questionable Treatments: A Study ofthe American Public,” conducted for the U.S.Department of Health and Human Services, studynumber 833015, September 1987.hmx, K., Insurance Investigator, Life and HealthComplaint and Investigation Unit, Maryland StateInsurance Commission, Baltimore, MD, personalcommunication, September 1988.Imwell, J., “Cancer Quacks Plead Guilty,” Nutri-tion Forum 2(5):36, 1985.Jmwell, J., “The Gerson Clinic,” Nutrition Forum3(2):9-12, 1986.Lund, J., “The Ojibway Wonder Drug. Can EssiacCure Cancer?” North Bay Nugget, April 9, 1988.Lyall, D., Schwartz, S., Herter, F.P., et al., “Treat-ment of Cancer by the Method of Revici, ’ J.A.M.A.194(3):165-166, 1965.Macdonald, J. S., “Point/Counterpoint: NCI Clini-cal Alert Policy: Point 1: Sometimes a GreatNotion,” J. Natl. Cancer Inst. 82(2):102-106, 1990.Ma.isin, J., Honorary Director, Institut du Cancer,Cliniques Universitaires St. Raphael, Louvain, Bel-gium, letters to E. Revici, Institute of AppliedBiology, February 26, 1%5, March 8, 1967, March8, 1968, March 18, 1968, November 11, 1969, andJanuary 13, 1970.Mamer, H., oral presentation in seminar held onSeptember 25, 1987, King of Prussia, PA, video-tape.Manner, H.W., DiSanti, S.J., Maggie, M.I., et al.,“Amygdalin, Vitamin A and Enzyme InducedRegression of Murine Mamrnary Adenocarcino-mas,” J. Manipulative Physiol. Ther. 1(4):246-248,1978.Manner, H.W., DiSanti, S.J., and Michalsen, T.L.,The Death of Cancer (Evanston, IL: Advanced

References .275

577.

578.

579.

580.

581.

582.

583.

584.

585.

586.

587.

588.

589.

590.

591.

Century Publishing Co., 1978).Mannisto, M., “Proposed Payment Changes RaiseQuality, Innovation and Medical Judgment Issues,”J. Cancer Program Management 3(1):9-15, Winter1988.Markle, G.E., and Petersen, J.C. (eds.), Politics,Science, and Cancer: The Luetrile Phenomenon(Boulder, CO: Westview Press for the AmericanAssociation for the Advancement of Science, Wash-ington, DC, 1980).Markman, M., “Medical Complications of ‘Alter-native’ Cancer Therapy,” (letter) N. EngZ. J. Med.312(25):1640, 1985.Maruo, T, Cohen, H., Segal, S.J., et al., “Produc-tion of a Chononic Gonadotropin-like Factor by aMicroorganism,’ Proc. Nat. Acad. Sci. USA 76(12):6622-6626,1979.Masuyama, K., Ochiai, H., Niwayama, S., et al.,“Inhibition of Experimental and Spontaneous Pul-monary Metastasis of Murine R~(+) Sarcoma byBeta-cyclodextrin-benzaldehyde,” Jpn. J. CancerRes. (Gann) 78:705-711, 1987.Mather, J.M., Carrothers, A.W.R., Harlow, N., et al.,Report of a Committee of Faculty Members of theUniversity of British Columbia Concerning theHoxsey Treatment for Cancer (Vancouver, Canada:University of British Columbia, 1957).Matthews-Simonton, S., Simonton, O. C., andCreighton, J.L., Getting Well Again (New YorkNY: Bantarn, 1978).Mattman, L.H., Cell WaZZ Deficient Forms (Cleve-land, OH: CRC Press, 1974).Maxwell, D.M., “Increased Cyanide Values in aLaetrile User,” Can. Med. Assoc. J. 119:18, 1978.Mayer, R.A., “Ozone: A Chemotherapeutic Agentfor the Treatment of Acute Monocytic IAdcemia inRats and Mammary Adenocarcinorna in Mice,”typescript, undated.McAllister, C.J., Scowden, E.B., Dewberry, F.L., etal., “Renal Failure Secondary to Massive Infusionsof Vitamin C,” J.A.M.A. 252:1684, 1984.McCabe, E., Oxygen Therapies. A New Way ofApproaching Disease (Morrisville, NY: EnergyPublications, 1989).McCabe, M., Coordinator for Group C/IL-2 Pro-gram, Cancer Therapy Evaluation program, Na-tional Cancer Institute, National Institutes ofHealth, U.S. Department of Health and HumanServices, Bethesda, MD, personal communication,August 1988.McCarty, M.F., “Aldosterone and the GersonDiet—A Speculation,” Med. Hypotheses 7:591-597, 1981.McCormick, D.L., and Spicer, A.M., “Nordihy-droguaiaretic Acid Suppression of Rat Mammary

592.

593.

594.

595.

596.

597.

598.

599.

600.

601.

602.

603.

604.

605.

606.

607.

608.

CarcinogenesisInducedby N-methyl-N-nitms-”Cancer Lett. 372:139-146, 1987.McDermott, P., personal communication, March 9,1990.McGrady, P., Sr., The Persecuted Drug: The Storyof DMSO (New York, NY: Charter Books, 1979).McGrady, P.M., Jr., “The Cancer Patient’s Quan-dary,” The Newsday Magazine pp. 10-16,4344,September 30, 1984.McGrady, P.M., Jr., Director, CANHELP, PortLudlow, WA, personal communication, March1987.McGrady, P.M., Jr., Statement before Office ofTechnology Assessment Advisory Panel, March 9,1990.McKee, D.L., “Emanuel Revici MD. A Review ofHis Scientific Work” Institute of Applied Biology,New York NY, March 1985.McKnight, F., Rudolf Steiner and Anthroposophy(New York, NY: Anthroposophical Society ofAmerica, 1967).McLaughlin v. Connecticut General Life InsuranceCompany, 565 F. Supp. 434, 438440 (N.D. Cal.1983) as cited in G.P. Monaco, “Is the BenefitPackage Fair to the Cancer Patient?” unpublishedpaper presented at American Cancer Society Work-shop on Employment, Insurance and the CancerPatient, New Orleans, LA, December 15-17, 1986.McLaughlin v. Connecticut General Life InsuranceCompany, 565 F. Supp. 434 (N.D. Cal. 1983).McLellan, L., Insurance Examiner, Health, Insur-ance Board of the District of Columbia, Washing-ton, DC, personal communication, June 1988.Mead, J.A.R., Acting Associate Director, Develop-mental Therapeutics Program, Division of CancerTreatment, National Cancer Institute, National In-stitutes of Health, U.S. Department of Health andHuman Services, Utter to J.D. Sproul, HealthProtection Branch, Health and Welfare Canada,Vanier, Ontario, December 1, 1983.Meares, A., “Regression of Cancer After IntensiveMeditation,” Med. J. Aust. 2(5):184, 1976.Meares, A., “Regression of Osteogenic SarcomaMetastasis Associated With Intensive Meditation,”Med. J. Aust. 2(9):433, 1978.Meares, A., “Meditation: A Psychological Ap-proach to Cancer Treatment,” Practitioner 222:119,1979.Meares, A., “Regression of Cancer of the RectumAilerIntensiveMeditation,’’Med. J. AuSt. 2(10):539-540, 1979.Meares, A., ‘‘What Can the Cancer Patient ExpectFrom Intensive Meditation?” Aust. Fare. Physician9:322-325, 1980.Meares, A., ‘Stress, Meditation and the Regressionof Cancer,” Practitioner 226:1607-1609, 1982.

276 ● Unconventional Cancer Treatments

609.

610.

611.

612.

613.

613a.

613b.

613c.

614.

615.

616.

617.

618.

Meares, A., “A Form of Intensive MeditationAssociated With the Regression of Cancer,” Am. J.Clin. Hypn. 25(2-3):114-121, 1982-83.Meares, A., “Psychological Mechanisms in theRegression of Cancer,” Med. J. Aust. 1(12):583-584, 1983.Medical Benefits, “Health Fraud: The FDA’sCampaign is One-Sided,” Medical Benefits, May30,1988 (reprinted from HeaZthfacts, May 1988).Melia, T, “The Wellness Community Lives Up ToIts Name For Cancer Patients,” LACMA Physician,October 19, 1987.The Merck Manual of Diagnosis and Therapy, 12thcd., David N. Holvey (editor-in-chief) (Rahway, NJ:Merck Sharp & Dohme Research lxiboratories,1972).The Merck Manual of Diagnosis and Therapy,13th cd., Robert Berkow (editor-in-chief)(Rahway, NJ: Merck Sharp & Dohme ResearchLaboratones, 1977).The Merck Manual of Diagnosis and Therapy,14th cd., Robert Berkow (editor-in-chief)(Rahway, NJ: M&ck Sharp & Dohme ResearchLaboratories, 1982).The Merck Manual of Diagnosis and Therapy,15th cd., Robert Berkow (editor-in-chief)(Rahway, NJ: Merck Sharp & Dohme ResearchLaboratones, 1987).

Middleton, M., “Federal Judge Finds AMA Con-spired Against Chiropractors,” The National LawJournal, p. 9, September 14, 1987.Miller, M., “Cancer and What It Means To You,”typescript obtained fkom Medical Research, Inc.,Las Vegas, NV, undated.Miller, M., A Little Dab Will Do Ya! DMSO: TheDrug of the 80’s (Las Vegas, NV: Medical Re-search, hlC.) undated.

Miller, M., untitled typescript, obtained fkom Medi-cal Research, Inc., Las Vegas, NV, undated.Mitchell, H.K., “llunor-inducing Factor in Droso-phila,” Science 133:876, 1961. -

618a. Mitchell, H.K., California Institute of Technology,

619.

620.

621.

622.

Pasaden~ CA, personal communication, Nove-rn~ber 3, 1988.

Moertel, C.G., correspondence, N. EngZ. J. Med.307(2):120, 1982.Moertel, C.G., Ames, M.M., Kovach, J. S., et al., “APharmacologic and Toxicological Study of Amygda-I.i.n,” JA.A4A. 245(6):591-594, 1981.Moertel, C.G., and Creagan, E.T., “Vitamin CTherapy of Advanced Cancer,” (letter, reply) N.Engl. J. Med. 302(12):694-695, 1980.Moertel, C.G., Fleming, llR., Creagan, E.T., et al.,“Highdose Vitamin C Versus Placebo in theTreatment of Patients With Advanced Cancer Who

623.

624.

625.

626.

627.

628.

629.

630.

631.

632.

633.

634.

635.

Have Had No Prior Chemotherapy,” N. Engl. J.Med. 312(3):137-141, 1985.Moertel, C.G., Fleming, ‘llR., Rubin, J., et al., “AClinical Trial of Amygdalin (Laetrile) in the Treat-ment of Human Cancer, ’’N. Engl. J.Med. 306(4):201-206, 1982.Mohs, F.E., “Chemosurgical Treatment of Cancerof the Skin. A Microscopically Controlled Methodof Excision,” J.A.M.A. 138(8):564-569, 1948.Mohs, F.E., Chemosurgery; Microscopically Con-trolled Surgery for Skin Cancer (Springfield, IL:Charles C. Thomas, 1978).Moikeha, D.H., and Hokam~ Y., “Effect of CrudeTabebuia Extracts In Vitro andZn Vivo on Macroph-ages and Lewis Lung Carcinoma in C57B1/6JMice,’ unpublished manuscript, Department ofPathology, John A. Burns School of Medicine,University of Hawaii, Honolulu, HI. Presented tothe Minority Biomedical Symposium, New Or-1eans, LA, April 1986.Monaco, G.P., “TheImpact of the Laetrile Phenom-enon on the Legal Profession: Technology byExperiment or Technology by Oath Helpers, Partn,” Jurimetrics Journal of LUW, Science andTechnology 21(3):285-328, 1981.Monaco, G.P., “Is the Benefit Package Fair to theCancer Patient?” paper presented at the AmericanCancer Society, Workshop on Employment, Insur-ance and the Cancer Patient, New Orleans, LA,December 15-17, 1986.Monaco, G.P., “Legal Implications, Freedom ofChoice and Insurance Problems With Questionableand Unproven Methods,” paper presented at theAmerican Cancer Society, Florida Division, HealthFraud Conference, Ft. Lauderdale, FL, November21, 1987.Monaco, G.P., “Alert,” Washington, DC, January13, 1988.Monaco, G.P., Advisory Panel member, EmpriseInc., Washington, DC, (formerly, Attorney, White,Fine and Verville, Washington, DC), personalcommunications, April 1988, September 1988,September 1989, November 6, 1989, and April1990.Monaco, G.P., and Burke, R.L., “Insurer as Gate-keeper: Handling Claims for Unproven Methods ofMedical Management,” The Forum 18(4):591-614,surnrner 1981.Monaco, G.P., andBurke,R.L., “Insumras&ekeepw—Part Two: Policy Obstacles in Unproven MethodsLitigation,’ The Forum 20(3):400417, Spring1985.Monte, T, “An MD Heals Himself of Cancer,”East West J., pp. 35-39, March 1980.Monte, T., “An MD Who Conquered His Cancer,”Saturday Evening Post 252:36, September 1980.

References .277

636.

637.

638.

639.

640.

641.

642.

643.

644.

645.

646.

647.

648.

649.

650.

651.

652.

Monte, T., The Way of Hope. Michio Kushi’sAnti-AIDS Program. Strengthening the ImmuneSystemThroughMacrobiotics, WarnerBooks, 1989.Moore, E., Blue Cross and Blue Shield Association,Chicago, IL, personal communication, June 7,1990.Moore, G., Chief, Division of Surgical Oncology,Denver General Hospital, Denver, CO, personalcommunication, October 28, 1988.Morgenstern, H., Gellert, G.A., Walter, S.D., et al.,“The Impact of a Psychosocial Support Program onSurvival With Breast Cancer: The Importance ofSelection Bias in Program Evaluation,” J. Chron.Dis. 37(4):273-282, 1984.Morishige, F., and Murata, A., “Prolongation ofSurvival Times in Terminal Human Cancer byAdministration of Supplemental Ascorbate,’ J. Int.Acad. Prev. Med. 5(1):47-52, 1979.Morris, L. C., Senior Vice President, Health BenefitsMamgement, Blue Cross and Blue Shield Associa-tion, Chicago, IL, personal communication, June1988.Morris, N., “Potential for Tragedy in Public Over-play of Cancer ‘Cures,’ “ Can. Med. ASSOC. J.113(5):465,470, September 6, 1975.Morrone, J.A., “Chemotherapy of Inoperable Can-cer. Preliminary Report of 10 Cases Treated withLaetrile,” Exp. Med. Surg. 20:299-308, 1962.Morse, D.L., Boros, L., and Findley, P.A., “Moreon Cyanide Poisoning from Laetrile,” N. Engl. J.Med. (letter), 301(16):892, 1979.Moss, R.W., The Cancer Syndrome (New YorlqNY: Grove Press, 1980).Moss, R.W., “Hydrazine Sulfate: Unorthodox Che-motherapy,” The Cancer Syndrome (New YorkNY: Grove Press, 1980).Moss, R.W., “The Promise of Hydrazine Sulfate,”Penthouse, January 1983.Moss, R.W., The Cancer Industry: Unraveling thePoZitics (New YorQ NY: Paragon House, 1989).Moxley, J.H., “Information Report of the Councilon Scientific Affairs: Health Fraud Report,” (Chi-cago, IL: American Medical Association, 1986).Moxley, J.H., “Informational Report of the Councilon Scientific Affairs. Issues in Health Fraud:CoIonic Irrigation,’ Chicago, IL, American Medi-cal Association, February 1987.Mullan, F., and Hoffman, B. (eds.), Charting theJourney: The Cancer Survivors’ Almanac of Re-sources (Mt. Vernon, NY: Consumer Reports Books,1990).Mumhv. G.P., Institute Director, Roswell ParkMerno~ Institute, letter to R. Brown, March 4,1976.

652a. Myers, R., Bausman, PA, letter and comments,March 9, 1990.

653.

654.

655.

656.

657.

658.

659.

660.

661.

N.Y Fare. Ct. Act, Section 1o11, as cited inG.M. Lerner, and J.E. Weeks, “The Laetrile PowerPlay in Drug Marketing,” Harnline Law Review3(1):1-50, 1980.National Academy of Sciences, Institute of Medic-ine, Division of Health Care Sewices, AlliedHealth Services: Avoiding Crises. Report of a Study(Washington, DC: National Academy Press, June1988).National Alliance Of Postal and Federal Employees,“Alliance Health Benefit Plan,” Washington, DC,January 1988.The National Council Against Health Fraud, “AnInvitation to Join in Combating Health Frau4Misinformation, and Quackery,” Natioti CouncilAgainst Health Fraud, Inc., Loma Linda, CA,undated.National Federation of Federal Employees, “NFFEHealth Benefit Plan,” Washington, DC, January1988.National Health Fraud Conference, “NationalHealth Fraud Conference 1988,” unpublished bro-chure, Kansas City, MO, 1988.National Post Office Mail Handlers, Watchmen,Messengers and Group Leaders Division of LIUNA,AFL-CIO, “Mail Handlers Benefit Plan,” Wash-ington, DC, January 1988.National Research Council, Diet, Nutrition, andCancer (Washington, DC: National Academy Press,1982).National Research Council, Diet and HeaZth: ImpZi-catiow for Reducing Chronic Disease Risk (Wash-ington, DC: National Academy Press, 1989).

661a. National Research Council, Food and Nutrition

662.

663.

664.

665.

666.

667.

Board, Recommended Dietary Allowances, Iothed. (Washington, DC: National Academy Press,1989).

Navarro, M.D., “Laetrile Therapy in Cancer,”Philippine J. Cancer 4: 204-209, 1962.Nelson, M., Bio-Medical Center, Tijuana, Mexico,personal communication to participants of a CancerControl Society sponsored bus tour, July 1987.New Cures for Old Ailments. A Symposium (Wic-hita, KS: GeraId B. Winrod, Publisher, 1952).New Jersey Senate Committee on Institutions,Health, and Welfare, Assembly, No. 3295—L.1977, c. 318, statement quoted from N.J. Stat.Ann. $24:6F-1, West Supp., 1987.New York State Department of Health, “News,”press release no. 1/24/84-13 OPA, January 24,1984.Newbold, V., “Macrobiotics: An Approach to theAchievement of Health, Happiness, andlbrmony,”Doctors Look at Macrobiotics, E. Esko (cd.) (NewYork, NY: Japan Publications, 1988).

278 ● Unconventional Cancer Treatments

668.

669.

670.671.

672.

673.

674.

675.

676.

677.

678.

679.

680.

681.

682.

683.

684.

685.

686.

Newbold, V., “Remission of Cancer in Patients ona Macrobiotic Diet,” unpublished manuscript, un-dated.Newton, B.W., “The Use of Hypnosis in theTreatment of Cancer Patients,” Am. J. CZin. Hypn.25(2-3):104-113, 1982-1983.Nielsen Television Index, 1987.Nielsen, I., and Pedersen, R. S., “Life-ThreateningHypokalemia Caused by Liquorice Ingestion,”Lancet i(8389):1305, 1984.Nienhaus, J., Stoll, M., and Vester, F., “ThymusStimulation and Cancer Prophylaxis by ViscwnProteins,” Experiential 26:523-525, 1970.Nieper, H.A., “Interview and Consultation of 5June 1974,” typescript, obtained from the A. KeithBrewer Library, Richland Center, WI.Nieper, H.A., “The Nieper Regimen 1977 (CancerTherapy),” typescript obtained horn the A. KeithBrewer Library, Richland Center, WI, October 21,1977.Nieper, H. A., “The Non-toxic I_xmg-term Therapyof Cancer: Necessity, State of the Art, Trends,” J.Int. Acad. Prev. Med. 6(1):41-70, 1980.Nieper, H.A., “On the 1982 State of the Art inCancer Research and Cancer Therapy,” typescriptobtained from A. Keith Brewer Library, RichlandCenter, WI, April 1982.Nieper, H.A., Revolution in Technology, Medicineand Society (Oldenburg, Germany: MIT Verlag,1985).Nightingale, S.L., “From the Food and DrugAdministration,” J.A.M.A. 256(22):3075, 1986.Nightingale, S.L., “Irnmunoaugmentative Ther-apy,” American Family Practitioner 34(6):159-160, 1986.Nightingale, S.L., “Imrnunoaugmentative Therapy:Assessing an Untested Therapy,’ ’JAMA. 259(23):3457,1988.Nixon, D.W., “Nutrition and Cancer: AmericanCancer Society Guidelines, programs, and Initia-tives,” CA 40(2):71-75, 1990.Null, G., and Pitrone, A., “Suppression of NewCancer Therapies: Dr. Joseph Gold and HydrazineSulfate,” Penthouse, p. 97, January 1980.Null, G., and Steinrnan, L., “The Politics of Cancer:Suppression of the New Cancer Therapies: Dr.Lawrence Burton,” Penthouse p. 74, July 1980.Null, G., and Steinman, L., “Suppression of Alter-native Cancer Therapies: Dr. Josef Issels,” Pent-house p. 72, August 1980.Null, G., and Steinman, L., “The Vendetta AgainstDr. Burton,” Penthouse, p. 37, March 1986.Nussbaum, E., Recovery: From Cancer to HealthThrough Macrobiotics (New York, NY: JapanPublications, 1986).

687.

688.

689.

690.

691.

692.

693.

694.

695.

696.

697.

698.

699.

700.

701.

O’Donnell v. Georgia Osteopathic Hospital, Inc.,748 F2d 1543, 1547 (llth Cir. 1984) as cited inDallis v. Aetna, 768 F.2d 1303 (llth Cir. 1985).O’Regan, B., and Hirshberg, C., Spontaneous Re-mission: An Annotated Bibliography of SelectedArticles and Case Reports from the World i14edicalLiterature, Volume 1: Remission of Cancer prelimi-nary draft (Sausalito, CA: The Institute of NoeticSciences, 1990).Oberley, L.W., huthauser, S.W.H.C., Buettner,G.R., et al., “The Use of Superoxide Dismutase inthe Treatment of Cancer,” Pathology of OxygenToxicity, J.D. Balentine (cd.) (New York, NY:Academic Press, 1982).Ochoa, M., Jr., Wittes, R.E., and Krakoff, I.H.,“Trial of Hydrazine Sulfate (NSC-150014) inPatients with Cancer,” Cancer Chemother. Re-ports, Part 1, 59(6):1151-1154, 1975.Odell, W.D., and Griffin, J., “Pulsatile Secretion ofHuman Chorionic Gonadotropin in Normal Adults,”N. Engl. J. Med. 317(27):1688-1701, 1987.Ohio State Law Journal, “The Uncertain Applica-tion of the Right of Privacy in Personal MedicalDecisions: The Laetrile Cases,” Ohio State LuwJournal 42(2):523-550, 1981.Ohsawa, G., Zen Macrobiotics (Los Angeles, CA:Ohsawa Foundation, 1965).Oleson, J.R., “Hyperthermia,” Cancer Principleand Practice of Oncology 3rd cd., V.T. DeVita, S.Herlrnan, and S.A. Rosenberg (eds.) (Philadelphia,PA: J.B. Lippincott Company, 1989).Olsnes, S., Stirpe, F., Sandvig, K., et al., “Isolationand Characterization of Viscurnin, a Toxic ktinFrom Viscum album L. (Mistletoe),’ J. Biol. Chem.257(22):13263-70, 1982.One, K., “Secondary Hyperoxalemia Caused byVitamin C Supplementation in Regular Hemodialy-sis Patients,” Clin. Nephrol. 26:239-243, 1986.Ortega, J.A., and Creek, J.E., “Acute CyanidePoisoning Following Administration of LaetrileEnemas,” J. Pediatr. 93:1059, 1978.Osband, M.E., Lipton, J.M., Lavin, P., et al.,‘‘Histiocytosis-X. Demonstration of Abnormal Im-munity, T-cell Histamine H2-receptor Deficiency,and Successful Treatment with Thymic Extract,’ N.Engl. J. Med. 304(3):146-153, 1981.Osteen, A. M., “Medical Licensing Requirements,”JA.M.A. 258(8):1053-1054, 1987.Otten, S., and Rosazza, J.P., “Microbial Transfor-mations of Natural Antitumor Agents: Conversionof Lapachol to Dehydro-alpha-lapachone by Curvu-laria lunata,” Appl. Environ. Microbiol. 38:311-313, 1979.Ovejera, A.A., Houchens, D.P., Barker, A.D., et al.,“Inactivity of DL-arnygdalin Against HumanBreast and Colon Tumor Xenografts in Athymic

References .279

(Nude) Mice,” Cancer Treat. Rep. 62(4):576-578,1978.

702. Owen, T-Y, Wang, S-Y Chang, S-Y, et al., “ANew Antitumor Substanc~Lycobeta.ine,” K’oHsueh T’ung Pao 21(6);285-287, 1976.

703. Page, L., “SPEX Exam Aims to Test SpecificGroups of Licensed M.D.s,” Am. A4ed News31(19):11, hkty 20, 1988.

704. Passwater, R. A., Cancer and Its Nutritional Thera-pies (New Canaan, CT: Keats Publishing, 1983).

705. Patterson, J.T., The Dread Disease. Cancer andModern American Culture (Cambridge, MA: Har-vard University Press, 1987).

706. Patton, J.F., Director, Health Care AdministrativeSanctions, Office of Investigations, Office of theInspector General, U.S. Department of Health andHuman Services, Washington, DC, personal com-munication, November 30, 1989.

707. Patton, T., Supervising hwestigator, WashingtonState Health Department, Olympia, WA, personalcommunication, November 16, 1989.

708. Pauling, L., “Vitamin C Therapy of AdvancedCancer,” (letter) N. EngZ. J. Med. 302(12):694,1980.

709. Pauling, L., correspondence, N. EngZ. J. Med.307(2):118-119, 1982.

710. Pauling, L., and Moertel, C., “A Proposition:Megadoses of Vitamin C Are Valuable in theTreatment of Cancer: Affirmative (Pauling); Nega-tive (Moertel),” Nutr. Rev. 44(1):28-32, 1986.

711. Paxton, A., “Practitioners of Unorthodox CancerTreatments,” prepared for the Office of TechnologyAssessment, U.S. Congress, Washington, DC, May23,1988.

712. Paxton, A., Washington, DC, personal communica-tion, June 6, 1988.

713. Peck, A., “Emotional Reactions to Having Can-cer,’ Am. J. Roentgenol. Radium Ther. Nucl. Med.114:591-599, 1972.

714. People v. llrych, Super. Ct., bs Angeles Co., Cal.,No. A364118 (1983) as cited in R.D. Schwartz, andR.L. Burke, “kgal Constraints on the Availabilityof Unorthodox Cancer Treatments: Consumer Pro-tection Viewpoint,” prepared for the Office ofTechnology Assessment, U.S. Congress, Washing-

‘ ton, DC, April 1988.715. People v. Burroughs, Cal. Sup. Ct., Crim. No.

23151 (1984) as cited in R.D. Schwartz, and R.L.Burke, “I_egal Constraints on the Availability ofUnorthodox Cancer Treatments: Consumer Protec-tion Viewpoint,” prepared for the Office of Tech-nology Assessment, U.S. Congress, Washington,DC, April 1988.

716. People v. Privitera, 141 Cal. Rptr. 764 (Dist. Ct.App. 1977).

717. People v. Privitera, 23 Cal.3d 697,591 P.2d 919,153 Cal.Rptr. 431 (1979).

718. People v. Privitera, cert. denied 444 U.S. 949(1979).

719. Persinos, G.J., Editor, Washington Insight, NorthBethesda, MD, letter, March 20, 1990.

720. Petersdorf, R.G., Adams, R.D., Braunwald, E., etal.(eds.), Harrison’s Principles of Internal Medicine,loth cd., (New York NY: McGraw Hill, 1983).

721. Petersen, D., “New Britain Woman Looks forMiracle to Cure Child’s Cancer,” Hartford Cour-ant, September 3, 1988.

722. Petersen, J. C., and Markle, G.E., “The LaetrilePhenomenon: An Overview,” Politics, Science,and Cancer: The Laetrile Phenomenon, G.E. Mar-kle, and J.C. Petersen (eds.) (Boulder, CO:Westview Press for the American Association forthe Advancement of Science, Washington, DC,1980).

723. Pfarr, B., “Report from the Microbiology Labora-tory,” Annual Report for the Socie~ for CancerResearch, Arlesheim, Switzerland, 1986.

724. Pharmtech Research, Inc., 103 F.XC. 448 (1984).725. Phifips, X, “Review and Analysis of Lawrence

Burton’s Patented Processes and Products,” con-tract report to Office of Technology Assessment,U.S. Congress, Washington, DC, January 1989.

726. Physicians Association forAnthroposophicalMedi-cine, personal communication, March 24, 1990.

727. Pike, B.F., Phillippi, P.J., and Lawson, E.H., “SoapColitis,” N. Engl. J. Med. 285(4):217-218, 1971.

728. Porcelli, J. A., “Getting Well Again Unconvention-ally,” Cancer Victors Journal, 22(1):11, Spring1988.

729. Portloc~ C., Yale University School of Medicine,New Haven, CT, personal communication, May1988.

730. Prager, M., “Nutrition Expert Ordered to AidCancer Society,” Spokane Chronicle p. 3, April 20,1984.

731. Project Cure, “History,” unpublished mimeograph,Washington, DC, undated.

732. Project Cure, “1987 in Review,” unpublishedpaper, Washington, DC, undated.

733. Pruitt, J., Miami, l%, personal communication, June20, 1988.

734. RA. v. Prudential Insurance Co., No. L 8093-79(N.J. Super Ct. Law Div. August 6, 1982), benchslip opinion, as cited in G.P. Monaco and R. Burke,“Insurer as Gatekeeper: Handling Claims for Un-proven Methods of Medical Management,” TheForum 18(4):591-614, Summer 1981.

735. Ramirez, A.J., Craig, T.K.J., Watson, J.P., et al.,“Stress and Relapse of Breast Cancer,” B.M.J.298:291-293, 1989.

280 ● Unconventional Cancer Treatments

736.

737.

738.

739.

740.741.

742.

743.

744.

745.

746.

747.

748.

749.

750.

751.

752.

753.

Rae, K.V., McBride, TJ., and Olseson, J.J., “La-pachol as an Antitumor Agent: Recognition andEvaluation,” Proc. Amer. Assoc. CancerRes. 9:55,1967.Rae, K.V., McBride, XJ., and Olseson, J.J., “Rec-ognition and Evaluation of Lapachol as an Antitu-mor Agent, ’ Cancer Res. 28:1952-1954, 1968.Ravich,R.A.,letterto theeditor,.lA.A4A. 140(10):908,1949.Ravich, R.A., Institute of Applied Biology, letter toE. Pratt, Locust Valley, NY, November 12,1955.Ravich, R.A., New York, ~, letter, May 16,1990.Ravich, R.A., “Revici Method of Cancer Control.Evaluation of 1047 Patients with Advanced Malig-nancies Treated from 1946-1955,” unpublishedmanuscript, undated.Redd, W. H., ‘Behavioral Approaches toTreatment-Related Distress,” CA 38(3):138-145, 1988.Regelson, W., “The ‘Grand Conspiracy’ Againstthe Cancer Cure,” J.A.M.A. 243(4):337-339, 1980.Remen, N.R., personal communication to Office ofTechnology Assessment, U.S. Congress, March 21,1990.Rentea, R., Lyon, E., and Hunter, R., “BiologicProperties of Iscador: A Viscum aZbum Preparation.I. Hyperplasia of the Thymic Cortex and Acceler-ated Regeneration of Hematopoietic Cells Follow-ing X-irradiation, ” Lab. Invest. 44(1):4348, 1981.Research Institute Hiscia, “Directions forthe Use ofIscador in the Treatment of Malignant Conditions,”pamphlet, Society for Cancer Research, Arlesheim,Switzerland, 1986.Revici, E., Research in Physiopathology as a Basisof Guided Chemotherapy with Special Applicationto Cancer (Princeton, NJ: Van Nostrand, 1961).Revici, E. “Research and Theoretical Backgroundfor Treatment of the Acquired ImmunodeficiencySyndrome (AIDS),” Townsend Letter for Doctors45:1-13, February/March 1987.Revici, E., Statement, in “Congressional PublicHearing Before Congressman Guy V. Molinari onAlternative or Non-traditional Cancer Therapiesand Treatments by Emanuel Revici, MD,” NewYork, NY, March 18, 1988.Revici, E., “Analysis of the Report of the ClinicalAppraisal Group,” typescript, undated.Revici, E., and Ravich, R.A., “Anti-hemorrhagicAction of n-Butanol in Advanced Cancer,” AngioZ-Ogy 4:510-515, 1953.Rib6reau-Gayon, G., Jung, M.L., Baudino, S., et al.,‘‘Effects of Mistletoe (Viscum aZbumL.) Extracts onCultured Tumor Cells,” Experiential 42(6):594-599, 1986.Rib6reau-Gayon, G., Jung, M.L., DiScala, D., et al.,“Comparison of the Effects of Fermented and

754.

755.

756.

757.

758.

759.

760.

761.

762.

763.

764.

765.

766.

Unfermented Mistletoe Preparations on Culturedlhmor Cells,” OncoZogy 43(Suppl. 1):3541, 1986.Rice, J., and Steger, C., Executive Office, RoswellPark Memorial Institute, personal communicationto Office of Technology Assessment, U.S. Con-gress, May 1990.Richards, E., “Vitamin C Suffers a Dose ofPolitics,” New Scientist 109(1497):4649, 1986.Richards, E., “The Politics of Therapeutic Evalua-tion. The Vitamin C and Cancer Controversy,”Social Studies of Science 18:653-701, 1988.Richards, E., Science and Technology StudiesDepartment, University of Wollongong, Wollon-gong, Australia, personal communication, April 2,1990.Richardson, J. A., and Griffin, P., Laetrile CaseHistories. The Richardson Cancer Clinic Experi-ence (Westlake Village, CA: American Media,1977).Risner v. Blue Cross, Blue Shield ofMichigan, 15thJudicial District, Civ. 85-1619, as cited in G.P.Monaco, “hgal Implications, Freedom of Choiceand Insurance Problems With Questionable andUnproven Methods,” paper presented at the Ameri-can Cancer Society, Florida Division, Health FraudConference, Ft. huderdale, FL, November 21,1987.Robson, J.R.K., Kohland, J.E., Larkin, F.A., et al.,“Zen Macrobiotic Dietary Problems in Infancy,”Pediatrics 53:326-329, 1974.Rohe, F., and Kelley, W., Metabolic EcoZogy: AWay to Win the Cancer War (Winfield, KS:Wedgestone Press, 1983).Roper, M., Deputy Director, National Cancer Insti-tute, National Institutes of Health, U.S. Departmentof Health and Human Services, “NCI Interactionswith Proponents of Immunoaugmentative Ther-apy, ” typescript, April 2, 1990.Rosenberg, S.A., Longo, D.L. and Lotze, M.T.,“Principles and Applications of Biologic Ther-apy, ’ Cancer: Principles and Practice of Oncology3rd cd., V.T DeVit~ S. Hellman, and S.A. Rosen-berg (eds.) (Philadelphia, PA: J.B. Lippincott,1989).Rosenthal, L., Convention Director, Cancer ControlSociety, Los Angeles, CA, personal communica-tion, May 5, 1988.Rossi, B., Guidetti, E., and Deckers, C., “A ClinicalTrial of Chemotherapeutic Treatment of AdvancedCancers with a Synthetic L- Mandelonitrile Glucu-ronoside, ’ (abstract), 9th International Cancer Con-gress, Togo, Japan, 1966.Rothenberg, M., National Cancer Institute, NationalInstitutes of Health, U.S. Department of Health andHuman Services, Bethesda, MD, letter, September11, 1989.

References .281

767.

768.

769.

770.

771.

772.

773.

774.

775.

776.

777.

778.

779.

780.

781.

782.

Rovner, S., “For Cancer Drug, a Long Road toRecognition,” Washington Post, May 17, 1988.Rubino, M,J., and Davidoff, F., “Cyanide Poison-ing from Apricot Seeds,” J.A.M.A. 241:359, 1979.Ruffenach, G., “Scams on the Rise in HealthInsurance: Schemes Become More Elaborate, Mak-ing Them Harder to Uncover,” WaZZ Street Journal,June 22, 1988.Sackman, R., Executive Director, The Foundationfor Alternative Cancer Therapies, Ltd., New YorkNY, personal communication, May 1988.Salzer, G., “Adjuvante Misteltherapie bei Krebser-krankung,” Z. Allg. Med. 57:323-327, 1981.Saber, G., and Denc~ H., “Randomisierte StudieuberM “e&kamentbse Rezidiv- Pmphylaxemit 5-Fluom-Uricil und IscadorBeim Resezierten Magenkamm“ om-ErgebnisseEinerZwischenauswertung,’ ‘Krebsges-chehen 11:130-131, 1979Salzer, G., and Havelec, L., “Rezidivprophylaxebei Operierten Bronchusluuzinom-Patienten rnitdem Mistelpraparat Iscador. Ergebnisse Eines Klin-ischen Vershuchs aus den Jahren 1969-1971,”Onkologie 1:264-267, 1978.Salzer, G., and Havelec, L., “Adjuvante Iscador-Behandlung Nach Operiertem Magenkarzinom. Er-gebnisse Einer Randomisierten Studie,” Krebsges-chehen 15:106-110, 1983.Samid, D., Sherman, L.T., and Rimoldi, D., ‘Induc-tion of Phenotypic Reversion and Terminal Differ-entiation in ‘Ihmor Cells by Antineoplaston AS2-1,” abstract, 9th International Symposium on Fu-ture Trends in Chemotherapy, Geneva, Switzerlan~March 1990.Sattilaro, A.J., and Monte, T.J., “Physician, HealThyself,” Life, August 1982.Sattilaro, A.J., and Monte, XJ., Recalled by Life(New York NY: Avon, 1982).Saurat, J.-H., Didierjean, L., Merot, Y., et al.,“Blistering Skin Disease in a Man After Injectionsof Human Placental Extracts,’ ’l?J4J. 297(6651):775,1988.Sayre, J.W., and Kaymakcakm, S., “Hazards toHealth: Cyanide Poisoning from Apricot SeedsAmong Children in Central Twkey,” N. EngZ. J.Med. 270:1113, 1964.Schaffarzic~ R., Senior Vice-President and Medi-cal Director, Blue Shield of California, San Fran-cisco, CA, personal communication, September1988.Schapira, D.V., and Wenzel, L., “Florida CISInquiries About Unproven Methods of CancerTreatment and Immunotherapy,” Oncology Times,p. 12, June 1983.Scheffler, P., producer, “The Establishment v. Dr.Burton,” 60 Minutes 12(36), May 18, 1980.

783.

784.

785.

786.787.

788.

789.

790.

791.

792.

793.

794.

795.

796.

797.

798.

Schegg, K.M., and Welch, W., Jr., “The Effect ofNordihydroguaiaretic Acid and Related Lignans onFormyltetrahydrofolate Synthetase and Carboxy-lesterase,” Biochim. Biophys. Acta 788:167-180,1984.Schmidt, E. S., Newton, G.W., Saunders, S.M., etal., “Laetrile Toxicity Studies in Dogs,” J.A.M.A.239(10):943-947, 1978.Schmidt, K.H., Hagmaier, V., Hornig, D.H., et al.,‘‘Urinary Oxalate Excretion After Large Intakes ofAscorbic Acid in Man,” Am. J. CZin. Nutr. 34:305-311,1981.Schneider v. Revici, 817 F.2d 987 (2nd Cir. 1987).Schneider, A., program Administrator, Departmentof Technology Assessment, American MedicalAssociation, Chicago, IL, personal communication,March 1988.Schrad, K., Spokesman, Virginia Insurance Com-mission, Richmond, VA, personal communication,September 1988.Schuerholz, J., “The Legal Situation of Anthropos-ophicaI Medicine in the Federal Republic of Ger-many,” J. Anthroposophical Med., in press.Schultz, R., Staff Attorney, Texas State Board ofMedical Examiners, Austin, TX, personal commun-ication, November 22, 1989.Schwartz, R.D. and Burke, R.L., “~gal Constraintson the Availability of Unorthodox Cancer Treat-ments: Consumer Protection View,” contract reportfor the Office of Technology Assessment, U.S.Congress, Washington, DC, April 1988.Scott, N.E., and Farmer, J.F., Eating With Angels:The Neil Scott Story (New York, NY: JapanPublications, 1986).Segal, I., Tim, L.O., Hamilton, D.G., et al., “RitualEnema-Induced Colitis,” Dis. CoZonRectum 22:195-199, 1979.Seits, I.F., Gershanovich, M.L., Filov, V.A., et al.,“Experimental and Clinical Data of AntitumorAction of Hydrazine Sulfate,” Vopr. Onkd. 21(1):45-52,1975.Shealy, C.N., Advisory Panel member, ShealyInstitute for Comprehensive Health Care, letter,April 30, 1990.Sheehan, H.E., Director, Professional EducationProgram, American Cancer Society, New YorkNY, personal communication, October 1987.Sherlock, P., and Rothschild, E.O., “Scurvy Pro-duced by a Zen Macrobiotic Diet,” J.A.M.A.199(11):794-798, 1967.Shike, M., and Brennan, M.F., “Supportive Care ofthe Cancer Patient,” Cancer. Principles and Prac-tice of Oncology, 3rd cd., V.T. DeVita, Jr., S.Hellrnan, and S.A. Rosenberg (eds.) (Philadelphia,PA: J.B. Lippincott, 1989).

282 ● Unconventional Cancer Treatments

799.

800.

801.

802.

803.

804.

805.

806.

807.

808.

809.

810.

811.

812.

813.

814.

815.

Shinwell, E.D., and Gorodischer, R., “TotallyVegetarian Diets and Infant Nutrition,” Pediatrics70:582-586, 1982.Shragg, T.A., Albertson, TE., and Fisher, C.J.,“Cyanide Poisoning After Bitter Almond Inges-tion,” West. J. Med. 136:65-69, 1982.Shurnuke v. Travelers Insurance Co., No. 81-5769-CK, (Mich. Co. Cir. Ct. January 6, 1984) as cited inG.P. Monaco and R.L. Burke, “Insurer as Gate-keeper - Part Two: Policy Obstacles in UnprovenMethods Litigation,” The Forum 20(3):400-417,Spring 1985.Siegel, B. S., Love, Medicine, and Miracles (NewYork, NY: Harper and Row, 1986).Siegel, B. S., “ECaP,” unpublished form letter,New Haven, CT, Summer 1988.Siegel, B. S., Peace, Love, and Healing (New YorkNY: Harper and Row, 1989).Sikora, K., Professor of Clinical Oncology, RoyalPostgraduate Medical School, University of Imn-don, letter, February 14, 1990.Simonton, O. C., Matthews-Simonton, S., and T.F.Sparks, “Psychological Intervention in the Treat-ment of Cancer,” Psychosomatic 21(3):226-233,1980.Sirnonton, S.M., and Shook, R.L., The HealingFamiZy (New York, NY: Bantam Books, 1984).Sirnonton-Atchley, S., Little Rock, AR, personalcommunication, 1989.Smart, C.R., Hogle, H.H., Robins, R.K., et al., “AnInteresting Observation on NordihydroguaiareticAcid (NSC4291; NDGA) and a Patient WithMalignant Melanom*A Preliminary Report,”Cancer Chemother. Rep. Part 1, 53(2):147-151,1969.Smart, C.R., Hogle, H.H., Vogel, H., et al., “Clini-cal Experience With Nordihydroguaiaretic Acid,”Rocky Mountain Med. J. 11:394$3, 1970.Smith, F.P., Butler, T.P., Cohan, S., et al., ‘LaetrileToxicity: A Report of Two Cases,” (letter) J.A.M.A.,238(13):1361, 1977.Smith, L.H., “Symposium on Renal Lithiasis:Medical Evaluation of Urolithiasis: Etiologic As-pects and Diagnostic Evaluation,” UroZ. C/in.North Am. 1:241-260, 1974.Smith, R.D., “The Laetrile Papers,” The Sciences,pp. 10-13, January 1978.Srnits, H.L., Feder, J., and Scanlon, W., “Medi-care’s Nursing-Home Benefit: Variations in Inter-pretation,” N. Engl. J. Med. 307(14):855-862,September 30, 1982.Snyder, R., Executive Director, Payment Manage-ment, Blue Cross and Blue Shield Association,Chicago, IL,personalcommunication, August 1988.

816.

817.

818.

819.

820.

821.

822.

823.

824.

825.

826.

827.

828.

829.

830.

831.

Society for Cancer Research, “Information inBrief, ” pamphlet, CH-4144, Arlesheirn, Switzer-lan~ January 1982.Solomon, G.F., “Psychoneuroirnmunology: Inter-actions Between Central Nervous System andImmune System,” J. Neurosci. Res. 18:1-9, 1987.Sorensen, D.I., Devine, M.M., and Rivers, J.M.,“Catabolism and Tissue Levels of Ascorbic AcidFollowing Imngterm Massive Doses in the GuineaPig,” J. Nutr. 104:1041-1048, 1974.Speckhart, V.J., Norfo~ VA, personal communica-tion, February 1990.Speckhart, V.J., and Johnson, A., “Use of anAutogenous Vaccine in Cancer Patients: ImmuneAlteration and Tumor Response,” proposal for aninvestigational protocol submitted to the Institu-tional Review Board of the Medical College ofHampton Roads, Eastern Virginia Medical School,typescript, May 3, 1988.Spencer, H., “Vitamin C Ingestion, Gastritis, andAntacid Therapy,” J.A.M.A. 250:3228, 1983.Spencer, R.R., Chief, National Cancer Institute,National Institutes of Health, U.S. Department ofHealth and Human Services, letter to M. Gerson,March 21, 1947.Spiegel, D., and Bloom, J., “Group Therapy andHypnosis Reduce Metastatic Breast CarcinomaPain,” Psychosom. Med. 45:333, 1983.Spiegel, D., Bloom, J.R., Kraemer, H.C., et al.,“Effect of Psychosocial Treatment on Survival ofPatients With Metastatic Breast Cancer,” Lancet2(8668):888-891, 1989.Spingarn, N.D., National Coalition for CancerSurvivorship, Washington, DC, letter, March 12,1990.Spjut, R.W., and Perdue, R.E., “Plant Folklore: ATw1 for Predicting Sources of Antitumor Activ-ity?” Cancer Treat. Rep. 60(8):979-985, 1976.Spremulli, E.N., and Dexter, D.L., “Polar Solvents:A Novel Class of Antineoplastic Agents,” J. CZin.Oncol. 2(3);227-241, 1984.Spremulli, E.N., Wampler, G.L., and Regelson, W.,“Clinical Study of Hydrazine Sulfate in AdvancedCancer Patients,” Cancer Chemother. Pharrnacol.3:121-124, 1979.Sproul, J.D., “Antineoplastons A2, AS2-1, A3, A5and Al O,” Division of Endocrinology and Metabo-lism, Bureau of Human Prescription Drugs, Healthand Welfare Canada, memo to I.W.D. Henderson,Director, Bureau of Human Prescription Drugs,Health and Welfare Canada, March 15, 1985.St. John, R., Chief, Epidemiology, Pan AmericanHealth Organization, “Trip Report, Bahamas, July1-3, 1985,” typescript, undated.State of California Department of Health Services,Cease and Desist Order, issued February 16, 1990.

References ● 283

832.

833.

834.

835.

836.

837.

838.

839.

840.

841.

842.

843.

844.

845.

846.

847.

State of California, Division of Medical Quality,Board of Medical Quality Assurance, In the Matterof the Accusation Against: Michael L. Gerber,M.D., No. D-2990, N20092, May 21,1984.Stein, H.B., Hassan, A., and Fox, I.H., “AscorbicAcid-induced Uricosuria: A Consequence of Mega-vitamin Therapy,“ Ann. Intern. Med. 84:385-388,1976.Stein, M., “Stress, Depression, and the ImmuneSystem,” J. CZin. Psychiatry 50 (Suppl 5):3540,1989.Steinbach, H.L., Rousseau, R., McCormack, K.R.,et al., “Transmission of Enteric Pathogens byBarium Enemas,” J.A.M.A. 174:1207-1208, 1960.Stewart, F.W., Editor, Cancer-A Journal of theAmerican Cancer Society, New York, NY, letter toR.A. Ravich, Institute of Applied Biology, Decem-ber 15, 1950.Stock, C. C., Martin, D.S., Sugiura, K., et al.,“Antitumor Tests of Amygdalin in SpontaneousAnimal l_hmor Systems,” J. Surg. OncoZ. 10:89-123, 1978.Stock, C. C., Tarnowski, G. S., Schmid, F.A., et al.,“Antitumor Tests of Amygdalin in TransplantableAnimal Timor Systems,” J. Surg. Oncol. 10:81-88,1978.Stookey, H.E., Miller, B., and Meister, K.A.,“ACSH Survey: Do Health Food Stores GiveSound Nutrition Advice?” ACSH News & Viewspp. 7-14, May/June 1983.Sudan, R., Editorial Department, Bioscience Ed-iprint, Geneva, Switzerlan~ letter, September 6,1988.Suffness, M., ‘New Approaches to the Discovery ofAntitumor Agents,” Biologically Active NaturalProducts, K. Hostettmann, and P.J. Lea (eds.)(Oxford, England: Clarendon Press, 1987).SuUivan-Fowler, M., Medical Historian, Division ofLibrary and Information Management, AmericanMedical Association, Chicago, IL, personal com-munication, December 1987.Sullivan-Fowler, M., Austin, T, and Hafner, A.W.,Alternative Therapies, Unproven Methoak, andHealth Fraud. A Selected Annotated Bibliography,American Medical Association, Division of Libraryand Information Management, Chicago, IL, 1988.Sunnen, G.V., “Medical Hypnosis in the Hospital,”Advances 5(2):5-12, 1988.Swanson, N.A., “Mohs Surgery. Technique, Indi-cations, Applications, and the Future,” Arch. Der-matol. 119:761-773, 1983.Sweet, F., Kao, M.-S., Lee, S.-C.D., et al., “OzoneSelectively Inhibits Growth of Human CancerCells,” Science 209(4459):931-933, 1980.Swiss Society for Oncology, Swiss Cancer League,Working Group on Unproven Methods in Oncol-

848.

849.

850.

851.

852.

853.

854.

855.

856.

857.858.

859.

860.

861.

862.

863.

ogy, Iscador, File No. 10E, 1984.Takeuchi, S., Kochi, M., Sakaguchi, K., et al.,“Benzaldehyde as a Carcinostatic Principle inFigs,” Agr. Biol. Chem. 42:1449, 1978.Tayelq J.A., Heber, D., and Chlebowski, R.T.,“Effect of Hydrazine Sulphate on Whole-bodyProtein Breakdown in Lung Cancer Patients,”Lancet ii:241-244, 1987.Taylor, G.D., and ‘lhrner, A.R., “Cutaneous Ab-scess Due to Nocardia After ‘Alternative’ Therapyfor Lymphoma,” Can. Med. Assoc. J. 133:767,1985.Tennenbaum, D., Manager, Medical Necessity Pro-gram, Blue Cross and Blue Shield Association,Chicago, IL, September 1988.Terry, W., and Litv~ J., “Report to the Ministry ofHealth on the Site Visit to the Immunology Re-searching Centre, Ltd., Freeport, Grand BahamasIsland, Bahamas,” unpublished document, PanAmerican Hea.lthOrga.nization, Document BdXUTMS-5100, AMRO-1700, January 29-31, 1978.Thomsom, B., “Do Oxygen Therapies Work?,”East West, p. 70, September 1989.Thuning, C.A., Fanshaw, M. S., and Warren, J.,“Mechanisms of the Synergistic Effects of OralDimethyl Sulfoxide on Antineoplastic Therapy,”Ann. N.X Acad. Sci. 411:150-160, 1983.Todero, J., “People’s Verdict: Defend or CondemnNutrition,” Health Freedom News 7(9):25-9, Octo-ber 1988.Tom, M., Attorney, Prudential Insurance Companyof America, Newark, NJ, personal communication,September 1988.Travel King, Inc., 86 F.T.C. 715 (1975).Trombetta, L., Director of Public Information,Burzynski Research Institute, mailing addressed to“patients and friends,” typescript, February 8,1990.Tschetter, L., Creagan, E.’K, O’Fallen, J.R., et al.,‘‘A Community-based Study of Vitamin C (Ascor-bic Acid) Therapy in Patients With AdvancedCancer,” Proc. Am. Soc. Clin. Oncol. 2:92, 1983.‘Ihrner, F.J., “Hydrogen Peroxide and Other Oxi-dant Disinfectants,” Disinfection, Sterilization, andPreservation, 3rd cd., S.S. Block (cd.) (Philadelphia,PA: ha& Febiger, 1983).Tyler, V., The New Honest Herbal: A SensibleGuide to Herbs and Related Remedies (Philadel-phia, PA: G.F. Stickley, 1987).U.S. Congress, General Accounting Office, CancerPatient Survival: What Progress Has Been Made?,GAO/PEMD-87-13 (Washington, DC: March1987).U.S. Congress, Office of Technology Assessment,Assessing the Eficacy and Safety of Medical

284 ● Unconventional Cancer Treatments

864.

865.

866.

867.

868.

869.

870.

871.

872.

873.

874.

875.

Technologies, OTA-H-75 (Washington, DC: U.S.Government Printing Office, September 1978).U.S. Congress, Office of Technology Assessment,The Implications of Cost-Effectiveness Analysis ofMedical Technology, OTA-H-126 (Washington,DC: U.S. Government Printing Office, August1980).U.S. Congress, Office of Technology Assessment,Policy Implications of the Computed Tomography(CT) Scanner: An Update, BP-H-8 (Washington,DC: U.S. Government Printing Office, January1981).U.S. Congress, Office of Technology Assessment,Assessment of Technologies for Determining Can-cerRisksfrom the Environment, OTA-H-138 (Wash-ington, DC: U.S. Government Printing Office,1981).U.S. Congress, Office of Technology Assessment,Strategies for Medical Technology Assessment,OTA-H-181 (Washington, DC: U.S. GovernmentPrinting Office, September 1982).U.S. Congress, Office of Technology Assessment,Case Study #22, The Effectiveness and Costs ofAlcoholism Treatment HCS-22 (Washington, DC:U.S. Government Printing Office, March 1983).U.S. Congress, Office of Technology Assessment,The Impact of Randomized Clinical Trials onHealth Policy and Medical Practice, OTA-BP-H-22 (Washington, DC: U.S. Government PrintingOffice, August 1983).U.S. Congress, Office of Technology Assessment,Medical Technology and Costs of the Me&.careProgram, OTA-H-227 (Washington, DC: U.S. Gov-ernment Printing Office, July 1984).U.S. Congress, Office of Technology Assessment,Healthy Children: Investing in the Future, OTA-H-345 (Washington, DC: U.S. Government PrintingOffice, February 1988).U.S. Congress, Office of Technology Assessment,The Quality of Medical Care: Information forConsumers, OTA-H-386 (Washington, DC: U.S.Government Printing Office, June 1988).U.S. Congress, Office of Technology Assessment,Screening for Open-Angle Glaucoma in the Elderly(Staff Paper ##l in OTA’s Series on PreventiveHealth Services Under Medicare) (Washington,DC: Office of Technology Assessment, U.S. Con-gress, October 1988).U.S. Congress, Senate, Committee on Appropria-tions, Senate Report No. 100-189, p. 89, 1988.U.S. Congress, Senate, Committee on ForeignRelations, Subcommittee on S.1875, 79th Con-gress, 2nd session, Cancer Research, hearings, July1-3, 1946 (Washington, DC: U.S. GovernmentPrinting Office, 1946).

876.

877.

878.

879.

880.

881.

882.

883.

884.

885.

886.

887.

U.S. Department of Health and Human Services,Health Care Financing Administration, “MedicarePeer Review Organization Manual,” TransmittalNo. 15, HCFA-Pub. 19, Baltimore, MD, May 1987.U.S. Department of Health and Human Services,Health Care Financing Administration, “MedicareCarriers Manual Part 3- Claims Process,” transmit-tal no. 1204, August 1987.U.S. Department of Health and Human Services,Office of the Inspector General, Office of Analysisand Inspection, “MedicalLicensure and Discipline:An Overview,” Doe. No. P-01-86-00064, June1986.U.S. Department of Health and Human Services,Office of the Inspector General, Office of Analysisand Inspections, Inspection of Chiropractic Serv-ices Under Medicare OAI-05-8600002, August1986.U.S. Department of Health and Human Services,Public Health Service, Agency for Health CarePolicy and Research, “Medical Treatment Effec-tiveness Research Program Described,” ResearchActivities, AHCPR Pub. No. 127 (Rockville, MD:March 1990).U.S. Department of Health and Human Services,Public Health Service, Centers for Disease Control,“Diarrhea horn Herbal Te&New York, Pennsyl-vania,” MMH?R 27:248, 1978.U.S. Department of Health and Human Services,Public Health Service, Centers for Disease Control,“Cutaneous Nocardiosis in Cancer Patients Receiv-ing Immunotherapy Injections-Bahamas,’ MMWR33:471472,477, 1984.U.S. Department of Health and Human Services,Public Health Service, Centers for Disease Control,‘‘Isolation of Human T-lymphotrophic Vixus ~HI/Lymphadenopathy-associated Virus from SerumProteins Given to Cancer Patients,’ MMWR 34:489-491, 1985.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administra-tion, “DMSO: No Proof of ‘Miracles,’ “ FDAConsumer, pp. 28-29, September 1980.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Addnistra-tion, “Cell Therapy,” Talk Paper T84-78, Novem-ber 5, 1984.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administra-tion, “Summary of National Health Fraud Confer-ence, ’ unpublished, Washington, DC, September11, 1985.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administrat-ion, “Cellular Therapy (Niehans Cell Therapy;

References .285

888.

889.

890.

891.

892.

893.

894.

895.

896.

897.

898.

Siccacell Therapy),” Import alert notice, number66-03 revised, March 25, 1986.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administra-tion, “Immuno-Augmentative Therapy (IAT),”Import Alert 57-04, Regulatory Procedure ManualPart 9, Imports, Chapter 7-79, August 6, 1986.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administra-tion, “FDA Issues Alert Against Dangerous CancerRemedy,” FDA Talk Paper T86-60, August 7,1986.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administra-tion, “Alert Issued on Nieper ‘Therapies,’ “ FDATalk Paper T86-64, August 15,1986.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administra-tion, Import Operations, “Automatic Detention ofUnapproved New Drugs Promoted by Dr. HansNieper of West Germany,” No. 66-28 Revision,December 10, 1987.U.S. Department of Health and Human Services,Public Health Service, Food and Drug Administrat-ion, Press Office, “Alert Issues on Nieper ‘Thera-pies, ‘ “ T86-64, August 15, 1986.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute, National Cancer InstituteStatement, “Unproven Methods: The Gerson Ther-apy,” February 5, 1987.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute, unpublished data fromthe Surveillance, Epidemiology, and End ResultsfiOgr~, 1987.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute, “Clinical Alert,” mail-ing to physicians, May 1988.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute, Extramural Committee toAssess Measures of Progress Against Cancer,“Measurement of Progress Against Cancer,” J.Natl. Cancer Inst. 82:825-835, 1990.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute, unpublished typescript,undated.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute/American Society forClinical Oncology, unpublished survey results,1987.

899.

900.

901.

902.

903.

904.

905.

906.

907.

908.

909.

910.

911.

U.S. Department of Health and Human Services,Public Health Sexvice, National Institutes of Health,National Cancer Institute, Cancer Information Serv-ice, “Unproven Methods: Gerson Therapy,” un-published mimeograph, February 5, 1987.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute, Cancer Information Serv-ice, “Unproven Methods: Hydrazine Sulfate,”unpublished mimeograph, Apti 1, 1987.U.S. Department of Health and Human Services,Public Health Service, National Institutes of Health,National Cancer Institute, Cancer Information Serv-ice, statement about the Immunology ResearchingCentre (IRC), typescript, May 14, 1987.U.S. Department of Health, Education, and Welfare,National Commission for the Protection of HumanSubjects of Biomedical and Behavioral Research,The Belmont Report: Ethical Principles and Guide-lines for the Protection of Human Subjects ofResearch DHEW Pub. No. (OS) 78-0012 (Wash-ington, DC: U.S. Government Printing Office,1978).U.S. Department of Health, Education, and Welfare,Public Health Service, Food and Drug Administra-tion, “Laetrile. Commissioner’ sDecisionOn Status,”Federal Register 42(151):39768-39806, DocketNo. 77N-0048, August 5,1977.U.S. Department of Health, Education, and Welfare,Public Health Service, National Institutes of Health,National Cancer Institute, Conference on Spontane-ous Regression of Cancer, NCI Monograph 44:1-148, 1976.U.S. Department of Health, Education, and Welfare,Public Health Service, National Institutes of Health,National Cancer Institute, Developmental Thera-peutics Program, Screening data summary for NSC303260D, August 4, 1978.U.S. Department of Health, Education, and Welfare,Public Health Service, National Institutes of Health,National Cancer Institute, Office of Cancer Com-munications, “Background Information on Lae-trile. NCI Testing of Laetrile in “~s$” m-rescript, September 1977.U.S. Postal Service, Postal Inspection Service,Semi-Annual Report (Washington, DC: 1987).Uhler, S., Director, Special Investigations, Pennsyl-vania Blue Shield, Camp Hill, PA, personal com-munication, September 1988.Ullrnan, D., President, The Foundation for Homeo-pathic Education and Research, Oakland, CA,personal communication, February 26,1990.United States v. Articles of Food and Drug, 372F. Supp. 915,920-921 (N.D. Ga. 1974).United States v. Burzynsk” Cancer Research Insti-tute, 829 F.2d 1124, (5th Cir. 1987).

286 ● Unconventional Cancer Treatments

912.

913.914.

915.

916.

917.

918.919.920.

921.

922.

923.

924.

925.

926.

927.

928.

929.

930.

United States v. Burzynski Cancer Research Insti-tute, 819 F.2d 1301 (5th Cir. 1987), rh. dknied 829F.2d 1124, 1987.United States v. Dotterweich, 320 U.S. 277 (1943).United States v. Dotterweich, 320 U.S. 277 (1943),cited in J.H. Young, Emory University, Atlanta,GA, personal communication, March 1990.United States v. Durovic, No. 64 C.R. 668 N.D. Ill.,(1966).United States v. Harper, Police Court of the Districtof Columbia, 1908, cited in J.H. Young, EmoryUniversity, Atlant~ GA, personal communication,March 1990.United States v. Richardson, 588 F.2d 1235, (9thCir. 1978).United States v. Ruthe~ord, 442 U.S. 544 (1979).United States v. Ruthe~ord, 449 U.S. 937 (1980).United States v.l?uthe~ord, 616 F.2d 455 (l&h Cir.1980).University of the State of New Yor~ New YorkState Regents Committee on Professional Disci-pline, ‘Vote of the Board of Regents,’ calendar no.8342, Jtiy 29, 1988.University of the State of New York New YorkState Regents Committee on Professional Disci-pline, “Terms of Probation, Emanuel Revici, M.D.,”calendar no. 8342, July 29, 1988.University of the State of New York New YorkState Regents Review Committee, In the Matter ofthe Disciplinary Proceedz”ng Against Emanuel Re-vici, calendar no. 8342, June 27, 1988.Van den Berg, H., Dagnelie, P. C., and Van Stav-eren, W. A., “Vitamin B12 and Seaweed,” Lanceti(8631):242-243, Janumy 30, 1988.Van Staveren, W., and Dagnelie, P. C., “FoodConsumption, Growth, and Development of DutchChildren Fed on Alternative Diets,” Am. J. Clin.Nutr. 48:819-821, 1988.Wrro, J., “Ozone Application in Cancer Cases,”typescript of presentation at the 6th World Congresson Ozone, Washington, DC, May 22-26, 1983.Veisz, H., Partner, Kornstein, Veisz, and Wexler,New York NY, personal communication, May 14,1990.Venditti, J.M., Chief, Drug Evaluation Branch,National Cancer Institute, National Institutes ofHealth, U.S. Department of Health and HumanServices, memorandum to Acting Director, Divi-sion of Cancer Treatment, National Cancer Insti-tute, July 21, 1980, referring to NCI test #NSCB99979.Viebahn, R., “Twenty Five Years of PracticableOzone Therapy,” typescript, Hansler, West Ger-many, undated.Vodicka, B.E., “Medical Discipline: Part II. Consti-tutionalConsideration -The Police Power,” J.A.M.A.

931.

932.

933.

934.

935.

936.

937.

938.

939.

940.

9410

942.

943.

944.

945.

946.

947.

233(13):1427-28, 1975.Wagenfeld, M.O., Vissing, YM., Markle, G.E., etal., “Notes From the Cancer Underground: HealthAttitudes and Practices of Participants in the Lae-trile Movement,” Soc. Sci. Med. 13A(4):483485,1979.Wagner, P., and hwis, R.A., “Interaction BetweenActivated Nordihydroguaiaretic Acid and Deoxyri-bonucleic Acid,” Biochem. Pharrnacol. 29:3299-3306,1980.Walde, P.L.D., Algoma District Medicd Group,Sault Ste. Marie, Ontario, “Report, Visit to theBurzynski Research Institute, Houston, April 2-5,1982,” typescript, cover letter dated May 3, 1982.Walker, M., “Dr. William Donald Kelley ChargesContamination of Pancreatic Enzymes,” TownsendLetter for Doctors 65:535, December 1988.Walker, W.T., “Personal Observations on the Useof Iscador,” Br. Homeopath. J. 66:133-138, 1977.Warburg, O., The Prime Cause and Prevention ofCancer, 2d rev. ed. (Wirzburg, Germany: KonradTriksch, 1969).Ward, P. S., “Who Will Bell the Cat?” BuZZ. Hist.Med. 58:28-52, 1984.Ward, P. S., “History of Hoxsey Treatment,” pre-pared for the Office of Technology Assessment,U.S. Congress, Washington, DC, May 1988.Ward, P. S., “History of Gerson Therapy,” preparedfor the Office of Technology Assessment, U.S.Congress, Washington, DC, June 1988.Washuttl, J., Steiner, I., and Salzer, H., ‘Reaction ofan 02/03 Mixture on ‘Ibmor Tissue and HealthTissue In Vitro,” typescript obtained from Me-dizone International, undated.Watson, R., contract to OffIce of TechnologyAssessment, U.S. Congress, typescript, “Quality ofLife Assessment Instruments: A Review of 32Current Measures and One Classic,” 1988.Waxman, S., Scher, W., and Scher, B.M., “BasicPrinciples for Utilizing Combination Differentia-tion Agents,” Cancer Detect. Prev. 9:395407,1986.Wead, B., Second Opinion: LaPacho and theCancer Controversy (Vancouver, BC: RostrumCommunications, 1985).Wehmeyer v. Prudential, N.J. Sup. Ct., Civ. No.L-18383-81, 1983, as cited in G.P. Monaco, andR.L. Burke, “Insurer as Gatekeeper - Part Two:Policy Obstacles in Unproven Methods Litigation,”The Forum 20(3):400-417, Spring 1985.Weil, A., Health and Healing (Boston, MA:Houghton Mifflh, 1983).Weil, A., “A New Imok at Botanical Medicine,”Whole Earth Review 64:54-61, 1989.Weil, A., Advisory Panel member, University ofArizona, letter, March 20, 1990.

References ● 287

948.

949.

950.

951.

952.

953.

954.

955.

956.

957.

958.

959.

960.

%1.

962.

963.

964.

%5.

%6.

Weil, A., Natural Health, Natural Medicine (Bos-ton, MA: Houghton Mifflin, 1990).Weinberger v. Hynson, Westcott & Dunning, Inc.,412 U.S. 609,622, (1973).Weiner, M., “Should the Public Have the hgalRight to Use Unproven Remedies? Yes,” Contro-versies in Therapeutics, L. Lasagna (cd.) (Philadel-phia, PA: W.B. Saunders Company, 1980).Weiwel, F., President, I.A.T Patients’ Association,Inc., Otho, IA, personal communication, June 1988.Weleda Co., Spring Valley, ~, personal communi-cation, June 1989.Weleda Pharmacy, Inc., “Physicians Familiar WithAnthroposophical Remedies,” typescript, SpringValley, NY, January 1988.Wellness Community, “The Basis of the Wellnesscommunity,” Unpubliki mirneoz SantaMoni~CA, undated.Werner, M., “Report on Work on Iscador at theHiscia Institute,” Annual Report of the Society forCancer Research, Arlesheim, Switzerland, 1988.Wheeler, W.L., M.D., Secretary, Medical Society ofthe County of New York, letter to B. Lichello (S.J.Haught), National Enquirer, New York, April 23,1958.Widom, R., President, Immunology Research Foun-dation, Inc. of Great Neck, ~, letter to BahamianMinistry of Health, May 5,1975.Widom, R., Temple Emanuel, Great Neck, N.Y,personal communication, January 1988.Wigmore, A., The Wheatgrass Book (Wayne, NJ:Avery Publishing Group, 1985).Wilkv. American Medical Association, 671 F. Supp.1465 (N.D. Ill. 1987).Willheirn, R., Revici, E., Fluss, P., et al., “FurtherExperiments Concerning the Lytic Power of BloodSerum Against Ascites Tumor Cells,” Exp. Med.Surg. 17:272-281, 1959.Wilson, B., “The Rise and Fall of Laetrile,”Nutrition Forum 5(5):3340, 1988.Winn, R., Chairman, Unorthodox Practices Com-mittee, American Society for Clinical Oncology,Houston, TX, personal communication, October 14,1987.Wittes, R.E., “Noninvestigational Uses of Investi-gational Drugs: Some Implications of FDA’s Re-vised Regulations,’ J. Natl. CancerInst. 80(5):301-304, May 4, 1988.Wodinsky, I., and Swiniardki, J.K., “AntitumorActivity of Amygdalin MF (NSC- 15780) as aSingle Agent and With Beta-glucosidase (NSC-128056) on a Spectrum of Transplantable Rodentllmors,” Cancer Chemother. Rep., Part I, 59:939-950, 1975.Wolfe, S., Public Citizen Health Research Group,Statement on the Export of Unapproved Drugs,

%7.%8.

%9.

970.

971.

972.

973.

974.

975.

976.

977.

978.

979.

980.

before the Committee on Labor and Human Re-sources, U.S. Senate, Washington, DC, June 5,1985.Wolin v. United States, 108 S. Ct. 1026, (1988).Wo@er, S., Tijuana Clinics. 15 Years Analysis (LaMiranda, CA: Wolper, 1987).Woo, W. S., he, E.B., and Chang, I., “BiologicalEvaluation of Korean Medicinal Plants. II.,”YakAak Hoe Chi 21:177-183, 1977.Wrenn, K., “Fecal Impaction,” N. Engl. J. Med.321(10):658-662, 1989.Wuerthele-Casp6, V., “Presence of ConsistentlyRecurring Invasive Mycobacterial Forms in lkmorCells,” Micro-Organisms Associated With Neo-plasms: The Presence of Consistently RecurringInvasive Mycobacterial Forms in Tumor Cells, asymposium presented under the auspices of the NewYork Microscopical Society, March 19, 1948, N.XA4icroscopial Socie~ Bulletin 2(2):1, 1948.Wuerthele-Casp6, V., “Neoplastic Infections ofMan and Animals,” J. Am. Med. Worn. Assoc.10(8):261-266, 1955.Wuerthele-Casp6, V., Alexander-Jackson, E., An-derson, J.A., et al., “Cultural Properties and Patho-genicity of Certain Microorganisms Observed FromVarious Proliferative and Neoplastic Diseases,”Amer. J. Med. Sci. 220:636-648, 1950.Wuerthele-Casp6, V., Alexander-Jackson, E., andSmith, L.W., “Some Aspects of the Microbiologyof Cancer,” J. Am. Med. Worn. Assoc. 8(1):7-12,1953.Wuerthele-Casp6 Livingston, V., Cancer: A NewBreakthrough (Ims Angeles, CA: Nash Publishing,1972).Wuerthele-Casp6 Livingston, V., “Abscisic AcidTablets and Process,” U.S. Patent #3,958,025, May18, 1976.Wuerthele-Casp6 Livingston, V., and Alexander-Jackson, E., “An Experimental Biologic Approachto the Treatment of Neoplastic Disease,” J. Am.Med. Worn. Assoc. 20(9):858-866, 1965.Wuerthele-Casp6 Livingston, V., and Alexander-Jackson, E., “A Specific Type of Organism Cul-tured From Malignancy: Bacteriology and Pro-posed Classification, “Ann. N. YAcad. Sci. 174:636-654, 1970.Wuerthele-Casp6 Livingston, V., and Livingston,A.M., ‘Demonstration of Progenitor cryptocides inthe Blood of Patients With Collagen and NeoplasticDiseases,” Trans. N.11 Acad. Sci. 34(5) :433A53,1972.Wuerthele-Casp4 Livingston, V., and Livingston,A.M., “Some Cultural, Immunological, and Bio-chemical Properties of Progenitor cryptocides,”Trans. N.Y Acad. Sci. 36(6):569-582, 1974.

288 ● Unconventional Cancer Treatments

981.

982.

983.

984.

985.

986.

987.

988.

Yamamoto, A., “Essiac,” Can. J. Hosp. Pharm.41(3):158, 1988.Yasgur, S. S., “Can Cancer Be Destroyed By theBody’s Own Agents?” Modern Medicine 43:4045,January 1, 1975.Yellowlees, P., Greenfield, C., and McIntyre, N.,“Dirnethylsulphoxide-Induced Toxicity,” Lancetii:1004-1006, 1980.Young, J.H., The Medical Messiahs. A SocialHistory of Health Quackery in Twentieth-CenturyAmerica (Princeton, NJ: Princeton University, 1967).Young, J.H., “Laetrile in Historical Perspective,”Politics, Science, and Cancer: The Luetrile Phe-nomenon, G.E. Markle, and J.C. Petersen, (eds.)(Boulder, CO: Westview Press for the AmericanAssociation for the Advancement of Science, Wash-ington, DC, 1980).Zavertnick J., “Analysis of Evidence Presented byDr. Burton to the Legislators on IAT Therapy,”unpublished, December 9, 1981.Zavertnic~ J., advertisement in Florialz Associationof Clinical Oncology Journal, 1981.Zavertnick J., “kwning From the Past: TheLaetrile and IAT Experiences,’ paper presented at

989.

990.

991.

992.

993.

the National HealthFraud Conference, Kansas City,MO, March 15, 1988.

Zavertniclq J., Miami, FL, personal communication,1988.

Zonderman, A. B., Costa, P.T, and McCrae, R.R.“Depression As a Risk for Cancer Morbidity andMortality in a Nationally Representative Sample,”J.A.M.A. 262(9):1191-1195, 1989.

Zs.-Nagy, I., Lustyik, G., LuMcs, G., et al., “Corre-lation of Malignancy With the Int.racellularNa+ :K+Ratio in Human Thyroid Tumors,” Cancer Res.43:5395-5402, 1983.

Zuckerberg v. Blue Cross and Blue Shield, 119Misc.2d 834,464 N.YS. 2d 678 (N.Y Sup. 1983),as cited in G.P. Monaco, and R.L. Burke, “Insureras Gatekeeper - Part Two: Policy Obstacles inUnproven Methods Litigation,” The Forum 2w3):4Wl-417, Spring 1985.

Zuckerberg v. Blue Cross and Blue Shield, 67N.Y.2d 688, 490 N.E.2d 839, 499 N.YS.2d 920(1986).